



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 319/127, C07C 235/08, 247/04		A1	(11) International Publication Number: WO 99/33493
			(43) International Publication Date: 8 July 1999 (08.07.99)

(21) International Application Number: PCT/CA98/01185	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 22 December 1998 (22.12.98)	
(30) Priority Data: 60/113,658 23 December 1997 (23.12.97) US 60/073,852 2 February 1998 (02.02.98) US	
(71) Applicant (for all designated States except US): INEX PHARMACEUTICALS CORPORATION [CA/CA]; 100-8900 Glenlyon Parkway, Glenlyon Business Park, Burnaby, British Columbia V5J 5J8 (CA).	
(72) Inventor; and	Published
(75) Inventor/Applicant (for US only): ANSELL, Steven, Michael [ZA/CA]; 201-2010 W. 8th Avenue, Vancouver, British Columbia V6J 1W5 (CA).	With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(74) Agents: ROBINSON, J., Christopher et al.; Fetherstonhaugh & Co., Suite 2200, 650 West Georgia Street, Box 11560, Vancouver, British Columbia V6B 4N8 (CA).	

(54) Title: POLYAMIDE OLIGOMERS

(57) Abstract

The present invention relates to new polyamide oligomers. These oligomers can be conjugated to lipids, nucleic acids, peptides, proteins, etc. The oligomer-lipid conjugates can be used to form liposomes, virusomes, micelles, etc., optionally containing drugs or biological agents. The polyamide oligomers are heterobifunctional allowing the attachment of other suitable ligand compounds (e.g., a targeting moiety). In addition, methods of use for the liposomes, virusomes, micelles, etc., are provided.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

POLYAMIDE OLIGOMERS

FIELD OF THE INVENTION

The present application relates to a series of polyamide oligomers based on ω -amino (oligoethyleneglycol) alkanoic acid monomers. These compounds can be used as heterobifunctional crosslinkers which can be conjugated to a variety of biomaterials which include, *inter alia*, proteins, nucleic acids and lipids. Oligomer-lipid conjugates of this invention can be incorporated into liposomes, micelles and other drug delivery systems for a variety of purposes.

BACKGROUND OF THE INVENTION

The pharmacokinetics of liposomal formulations can be improved if the vesicles can be maintained in circulation. An important mechanism for clearance of liposomal formulations is thought to involve the adsorption of proteins onto the liposome surface which mediates subsequent clearance by the cells of the reticuloendothelial system (RES). This clearance may be reduced by the attachment of hydrophilic polymers, such as polyethyleneglycol (PEG), to the liposome surface. These polymers may act in one or both of two ways: (i) they may inhibit or stop protein adsorption on to the liposome's surface, or (ii) they may act as a "steric barrier" to inhibit interactions between the cells involved in clearance and any proteins that might be bound to the liposome surface. The steric barrier effect may also be used to inhibit aggregation in some systems.

PEG-lipid conjugates are used in some commercial liposome formulations to create a steric barrier at the liposome surfaces. PEG is attractive because it is cheap, readily available, non immunogenic and is soluble in all but the most apolar of solvents (*see*, Torchilin, *et al.*, *Biochim. Biophys. Acta.*, 1195:11-20 (1994); Part, *et al.*, *Biochim. Biophys. Acta.*, 1195:11-20 (1994); and Woodle, *et al.*, *Bioconjugate Chem.*, 5:493 (1994)). The latter properties allow easy conjugation to a wide range of substrates.

U.S. Patent No. 5,013,556 and European Patent Applications Nos. 0572 049 A2 and 0 354 855 describe liposomes bearing PEG moieties covalently linked to the


external surface. As described therein, the PEG moieties are linked to amino groups in the head group of at least one phospholipid species forming the liposomes.

U.S. Patent No. 4,426,330 describes phospholipids wherein the polar head group has been modified by covalent attachment of a PEG moiety. European Patent Application No. 0 220 797 A2 describes a process for the preparation of liposomes.

One major drawback of the use of polyethylene glycol is that it exists as a distribution of oligomers with different molecular weights. Further, batch to batch variation can occur. Thus, the properties of the PEG-bound liposomes will vary. What is needed in the art is a specific molecular weight material of defined length to allow selective properties to be imparted to liposomes or other drug delivery systems. The present invention fulfills this and other needs.

SUMMARY OF THE INVENTION

In one aspect, the present invention relates to an intrinsically heterobifunctional polyamide oligomer (PAO) of Formula I:




15

In Formula I, R is a functional group including, but not limited to, hydrogen, alkyl or acyl. R¹ is a functional group including, but not limited to, hydrogen or alkyl. In an alternative embodiment, R, R¹ and the nitrogen to which they are bound form an azido moiety. R², in Formula I, is a functional group including, but not limited to, hydrogen, optionally substituted alkyl, optionally substituted aryl or the side chain of any natural or synthetic amino acid or amino acid mimetic. R³, in Formula I, is a functional group including, but not limited to, halogen, hydroxy, alkoxy, mercapto, hydrazino, amino or NR⁴R⁵, wherein R⁴ and R⁵ are independently hydrogen or alkyl. In Formula I, the index "n" is an integer having a value ranging from 4 to 80; the index

"m" is an integer having a value ranging from 2 to 6; the index "p" is an integer having a value ranging from 1 to 4; and the index "q" is an integer having a value of 0 or 1.

5 The parentheses between R and R³ define a monomeric unit. There are "n" monomers in any given compound of Formula I. The values of m, p and q and the definitions of R¹ and R² may vary from monomer to monomer for any given value of "n" monomers.


In another aspect, this invention relates to a compound of Formula II:



(II)


10 In Formula II, R¹ is a functional group including, but not limited to, hydrogen or alkyl. A, in Formula II, is a functional group including, but not limited to, hydrogen, alkyl, acyl or a ligand. In an alternative embodiment, R¹, A, and the nitrogen to which they are bound form an azido moiety. B, in Formula II, is a functional group including, but not limited to, halogen, hydroxy, alkoxy, amino, NR⁴R⁵ (wherein R⁴ and R⁵ are independently hydrogen or alkyl), mercapto, hydrazino, diacylglycerolyl, dialkylglycerolyl, N,N-dialkylamino, 1,2-diacyloxy-3-aminopropane, 1,2-dialkyloxy-3-aminopropane and a ligand. In Formula II, the index "n" is an integer having a value ranging from 4 to 80; the index "m" is an integer having a value ranging from 2 to 6; the index "p" is an integer having a value ranging from 1 to 4; and the index "q" is an integer having a value of 0 or 1. As described above, the parentheses between R and R³ define a monomeric unit. There are "n" monomers in any given compound of Formula II. The values of m, p and q and the definitions of R¹ and R² can vary from monomer to monomer for any given value of "n" monomers.

In yet another aspect, this invention relates to a compound of Formula III:



In Formula III, R is a functional group including, but not limited to, hydrogen, alkyl or aryl. R¹ and R² are functional groups which may be the same or different and include, but are not limited to, hydrogen or alkyl. In another embodiment, R, R¹ and the nitrogen to which they are bound form an azido moiety. R⁶ and R⁷ are functional groups which may be the same or different and include, but are not limited to, hydrogen, optionally substituted alkyl or optionally substituted aryl, wherein the substituents include aryl, amino, carboxyl, thiol or hydroxy groups or the side chain of any natural or synthetic amino acid or amino acid mimetic. The index "v" is an integer having a value ranging from 2 to 40; the indexes "m" and "r" are independently selected and have values ranging from 2 to 6; the indexes "x" and "s" are independently selected and have values ranging from 1 to 4; z and t are independently 0 or 1; and R³, in Formula III, is a functional group including, but not limited to, halogen, hydrogen, alkoxy, mercapto, hydrazino, amino or NR⁴R⁵, wherein R⁴ and R⁵ are independently hydrogen or alkyl. The parenthesis between R and R³ define a monomeric unit. R¹, m, R⁶, z, x, r, R⁷ and t can be the same or different throughout the series of "v" monomers.

In still yet another aspect, this invention relates to a compound of Formula IV:



In Formula IV, R¹ and R² are functional groups which may be the same or different and include, but are not limited to, hydrogen or alkyl. R⁶ and R⁷ in Formula IV, are functional groups which may be the same or different and include, but are not limited to, hydrogen, optionally substituted alkyl or optionally substituted aryl, wherein the substituents include aryl, amino, carboxyl, thiol or hydroxy groups or the side chain

of any natural or synthetic amino acid or amino acid mimetic. The index "v" is an integer having a value ranging from 2 to 40; the indexes "m" and "r" are independently selected and have values ranging from 2 to 6; the indexes "x" and "s" are independently selected and have values ranging from 1 to 4; z and t are independently 0 or 1. A, in Formula IV, is a functional group including, but not limited to, hydrogen, alkyl, acyl or a ligand. In an alternative embodiment, R¹, A, and the nitrogen to which they are bound form an azido moiety. B, in Formula IV, is a functional group including, but not limited to, halogen, hydroxy, alkoxy, amino, NR⁴R⁵ (wherein R⁴ and R⁵ are independently hydrogen or alkyl), mercapto, hydrazino, diacylglycerolyl, dialkylglycerolyl, N,N-dialkylamino, 1,2-diacyloxy-3-aminopropane, 1,2-dialkyloxy-3-aminopropane and a ligand. The parenthesis between A and B define a monomeric unit. R¹, m, R⁶, z, x, r, R⁷ and t can be the same or different throughout the series of "v" monomers.

In certain aspects, the present invention relates to intrinsically heterobifunctional polyamide oligomers that serve, *inter alia*, as a replacement to PEG, because they have superior properties. In these aspects, the oligomeric structures defined herein provide the following surprising advantages over PEG. First, unlike PEG which exists as a distribution of molecular weights, the oligomers of the present invention are of known molecular weights. Second, the present invention relates to biodegradable oligomeric material. Third, the present oligomers are intrinsically heterobifunctional bridges that can be used without the need to activate the end groups as in PEG polymers. Fourth, the present oligomers are hydrophilic, thereby providing a convenient way to keep other material in solution. There are other advantages of this invention which will be apparent to those skilled in the art.

In yet another aspect, this invention relates to a liposome, a micelle, a virosome, a lipid-nucleic acid particle, or other drug delivery composition containing a lipid conjugated to the polyamide oligomer of Formula II or Formula IV.

In yet another aspect, a liposome, a micelle, a virosome, a lipid-nucleic acid particle, or other drug delivery composition contains surface-bound ligand molecules, targeting vectors, antibodies or reporter molecules to bind to specific target tissues or cells.

In another aspect, the compound of Formula II or Formula IV is a bridge, *i.e.*, a linker molecule, with at least one ligand molecule (*e.g.*, an antibody) covalently attached thereto. In a presently preferred embodiment, the compound of Formula II or

Formula IV is a bridge with at least two ligand molecules (e.g., an antibody and a therapeutic peptide) covalently attached thereto.

In still yet another aspect, this invention relates to a liposome, a micelle, a virosome, a lipid-nucleic acid particle, or other drug delivery composition for 5 administering a bioactive agent via the bloodstream.

In another aspect, this invention relates to a method of enhancing the blood-circulation time of liposomes, micelles, virosomes, lipid-nucleic acid particles or other lipidized drug delivery compositions administered intravenously. The enhanced circulation time is achieved by adding to the liposomes, micelles, virosomes, lipid-10 nucleic acid particles or other drug delivery compositions an amphipathic lipid derivatized with a compound of Formula II or Formula IV.

Other features, objects and advantages of the invention and its preferred embodiments will become apparent from the detailed description which follows.

BRIEF DESCRIPTION OF THE DRAWINGS

15 **Figure 1** illustrates the synthesis of suitable monomers exemplified by 14-amino-3,6,9,12-tetraoxatetradecanoic acid;

20 **Figure 2** illustrates the synthesis of a claimed oligomer exemplified by *octa*-(14-amino-3,6,9,12-tetraoxatetradecanoic acid);

25 **Figure 3** illustrates the synthesis of an oligomer lipid conjugate exemplified by N-(ω -N'-acetoxy-*octa*-(14'-amino-3', 6', 9', 12'-tetraoxatetradecanoyl))-1,2-distearoyl-*sn*-glycero-3-phosphoethanolamine ("ATTA8-DSPE");

30 **Figure 4** illustrates inhibition of aggregation of stearylamine/POPC (5:95) - DOPS/POPC (20:80) systems using the compounds of the present invention.

25 **Figure 5** illustrates *in vivo* clearance behavior of ATTA8-DSPE liposomes.

35 **Figure 6** illustrates various compounds of the present invention (A-C) and comparison compounds (D-E).

40 **Figure 7** illustrates the synthesis of a compound of the present invention, reagents used were (a) myristoyl chloride, Et₃N; (b) LiAlH₄, Et₂O; (c) NHS ester, Et₃N, and methylene chloride.

45 **Figure 8** illustrates the synthesis of compounds of the present invention, reagents used were (a) concentrated NH₃; (b) *tert*-butoxypyrocarbonate, Et₃N, EtOH; (c)

acyl chloride, Et₃N, methylene chloride; (d) trifluoroacetic acid; (e) NHS ester, Et₃N, and methylene chloride.

Figure 9 illustrates the inhibition of hemolysis of erythrocytes by cationic lipids.

5 Figure 10 illustrates the inhibition of complement activation by various vesicles.

10 Figure 11 illustrates clearance of sterically stabilized liposomes 20 hours post administration in female mice. [¹⁴C]-CHE labeled liposomes composed of POPC/chol/SBL (55:45; 5mM) were prepared in HBS (25 mM hepes, 150 mM NaCl, pH7.4) and administered to mice (200 μ L per animal) by intravenous tail vein injection. Serum was collected after 20 h and analyzed for radioactivity by liquid scintillation counting. Steric barrier lipid (SBL) = MePEGA-2000-DSPE, circles; ATTA8-DSPE, squares; ATTA4-DSPE, triangles; no SBL, diamond. Error bars represent standard deviation for 5 animals.

15 Figure 12 illustrates clearance of sterically stabilized liposomes 20 hours post administration in female mice using neutral steric barrier lipids. [¹⁴C]-CHE labeled liposomes composed of POPC/chol/SBL (50:45:5; 5 mM) were prepared in HBS (25 mM hepes, 150 mM NaCl, pH7.4) and administered to mice (200 μ L per animal) by intravenous tail vein injection. Blood (25 μ L) was collected 4 h post injection by tail nicks. Blood samples were digested in solvable and analyzed for radioactivity by liquid scintillation counting. Liposome levels were estimated based on estimated blood volume of 8%. Serum was collected after 20 h and analyzed for radioactivity by liquid scintillation counting. Liposome levels were estimated based on estimated serum volume of 4.55%. Error bars represent standard deviation for 5 animals.

20 25 Figure 13 illustrates lipid dose on circulation levels of antisense encapsulated vesicles. Effect of lipid dose on circulation levels of antisense encapsulated in DSPC/chol/AL- 1/SBL (20:45:25:10) vesicles at 24 hours. SBL = MePEGS-2000-Mcer, circles; ATTA8-DSPE, squares. Error bars represent standard deviation.

30 Figure 14 illustrates clearance of liposomes 1 hour post administration in female mice subjected to weekly administrations. Liposomes [DSPC/chol (55:45, circles); DSPC/chol/ATTA8-DSPE (50:45:5, triangles); DSPC/chol/MePEGC-2000-DSPE (50:45:5, squares)] labeled with [³H]-cholesteryl hexadecyl ether were prepared in

HBS (Hepes buffered saline; 20 mM Hepes, 145 mM NaCl, pH7.4) and diluted such that the injected lipid dose was 50 mg/kg/week. Lipid was administered by intravenous tail vein injections (200 μ L) at weekly intervals for three weeks. Blood (50 μ L) was collected 1 hour post injection by tail nicks. Mice were weighed at weekly intervals to estimate blood volume (8% body weight). Blood samples were digested in solvable and analyzed for radioactivity by liquid scintillation counting. Error bars represent standard deviation for 6 animals per time point.

5 **Figure 15** illustrates the effect of SBL (steric barrier lipid) on plasmid formulation.

10 **Figure 16 A-B** illustrates liver enzyme levels after administration of antisense encapsulated in DSPC/chol/AL- 1/SBL (20:45:25:10) vesicles. Shaded symbols represent SBL = MePEGS-2000-Mcer; open symbols represent SBL = ATTA8-DSPE. Fig 16A: LDH levels (circles); Fig 16B: AST levels (squares); ASL levels (triangles). Error bars represent standard deviation.

15 **Figure 17** illustrates single dose tolerability of encapsulated antisense oligonucleotide liposomes incorporating MePEGS-2000-Mcer (closed symbols) or ATTA8-DSPE (open symbols). Organs excised include liver (squares), kidney (inverted triangle), lung (circles) and spleen (triangle). Error bars represent standard deviation.

Figure 18 illustrates effect of steric barrier lipids on drug loading.

20 **Figure 19A-B** illustrates *in vitro* cytotoxicity of ATTA8. Fig 19A illustrates human cell lines; Fig 19B illustrates rodent cell lines.

25 **Figure 20A-F** illustrates liposomes comprised of stearylamine/CL (5:95; CL - stearylamine, Fig. 20 A-C; CL - DODAC, Fig 20 D-F) and DOPS/POPC/SBL (20:80-n:n; n = 0 - 10; SBL = MePEGS-2000-DSPE, Fig 20 A and D; ATTA8-DSPE Fig 20 B and E; ATTA4-DSPE, Fig 20 C and F) were prepared in buffer (10 mM hepes, 15 mM NaCl, pH7.4) and diluted to 1 mM. An aliquot of cationic liposomes (0.5 mL) was added to anionic liposomes (0.5 mL) in a cuvette and mixed vigorously. Photometric monitoring at 550 nm was started approximately 3-5 seconds after mixing. Absorbance measurements were taken at 10 second intervals for a total of 6 minutes (stearylamine) or at 15 second intervals for a total of 10 minutes (DODAC). were prepared in buffer (10 mM hepes, 15 mM NaCl, pH7.4) and diluted to 1mM. An aliquot of cationic liposomes (0.5 mL) was added to anionic liposomes (0.5 mL) in a cuvette and mixed vigorously. Photometric monitoring at 550 nm was started approximately 3-5

seconds after mixing. Absorbance measurements were taken at 10 second intervals for a total of 6 minutes (stearylamine) or at 15 second intervals for a total of 10 minutes (DODAC).

DEFINITIONS

5 The term "lipid" refers to a group of organic compounds that are esters of fatty acids and are characterized by being insoluble in water but soluble in many organic solvents. They are usually divided in at least three classes: (1) "simple lipids" which include fats and oils as well as waxes; (2) "compound lipids" which include phospholipids and glycolipids; (3) "derived lipids" such as steroids.

10 The term "vesicle-forming lipid" is intended to include any amphipathic lipid having a hydrophobic moiety and a polar head group, and which by itself can form spontaneously into bilayer vesicles in water, as exemplified by most phospholipids.

15 The term "vesicle adopting lipid" is intended to include any amphipathic lipid which is stably incorporated into lipid bilayers in combination with other amphipathic lipids, with its hydrophobic moiety in contact with the interior, hydrophobic region of the bilayer membrane, and its polar head group moiety oriented toward the exterior, polar surface of the membrane. Vesicle adopting lipids include lipids capable of adopting a non-lamellar phase, yet which are capable of assuming a bilayer structure in the presence of a bilayer stabilizing component. Bilayer stabilizing components 20 include, but are not limited to, polyamide oligomers of this invention (e.g., the compounds of Formulae II and IV), peptides, proteins, detergents, lipid-derivatives, PEG coupled to phosphatidylethanolamine and PEG conjugated to ceramides (see US Application Serial No.08/485,608, which is incorporated herein by reference).

25 The term "amphipathic lipid" refers, in part, to any suitable material wherein the hydrophobic portion of the lipid material orients into a hydrophobic phase, while a hydrophilic portion orients toward the aqueous phase. Amphipathic lipids are usually the major component of a lipid vesicle. Hydrophilic characteristics derive from the presence of polar or charged groups such as carbohydrates, phosphato, carboxylic, sulfato, amino, sulfhydryl, nitro, hydroxy and other like groups. Hydrophobicity can be 30 conferred by the inclusion of apolar groups that include, but are not limited to, long chain saturated and unsaturated aliphatic hydrocarbon groups and such groups substituted by one or more aromatic, cycloaliphatic or heterocyclic group(s). Examples of

amphipathic compounds include, but are not limited to, phospholipids, aminolipids and sphingolipids. Representative examples of phospholipids include, but are not limited to, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoyl phosphatidylcholine, lysophosphatidylcholine, 5 lysophosphatidylethanolamine, dipalmitoylphosphatidylcholine, dioleoylphosphatidylcholine, distearoylphosphatidylcholine or dilinoleoylphosphatidylcholine. Other compounds lacking in phosphorus, such as sphingolipid, glycosphingolipid families, diacylglycerols and β -acyloxyacids, are also within the group designated as amphipathic lipids. Additionally, the amphipathic lipids 10 described above may be mixed with other lipids including triglycerides and sterols.

The term "neutral lipid" refers to any of a number of lipid species which exist either in an uncharged or neutral zwitterionic form at physiological pH. Such lipids include, for example, diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, cephalin, cholesterol, cerebrosides and diacylglycerols.

15 The term "non-cationic lipid" refers to any neutral lipid as described above as well as anionic lipids. Examples of anionic lipids include, but are not limited to, phosphatidylglycerol, cardiolipin, diacylphosphatidylserine, diacylphosphatidic acid, N-dodecanoyl phosphatidylethanolamines, N-succinyl phosphatidylethanolamines, N-glutaryl phosphatidylethanolamines, lysylphosphatidylglycerols, and other anionic modifying 20 groups joined to neutral lipids.

The term "cationic lipid" refers to any of a number of lipid species which carry a net positive charge at physiological pH. Such lipids include, but are not limited to, N,N-dioleyl-N,N-dimethylammonium chloride ("DODAC"); N-(2,3-dioleyloxy)propyl-N,N,N-trimethylammonium chloride ("DOTMA"); N,N-distearyl-N,N-dimethylammonium bromide ("DDAB"); N-(2,3-dioleyloxy)propyl-N,N,N-trimethylammonium chloride ("DOTAP"); 3 β -(N-(N',N'-dimethylaminoethane)-carbamoyl)cholesterol ("DC-Chol") and N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl ammonium bromide ("DMRIE"). Additionally, a number of commercial 25 preparations of cationic lipids are available which can be used in the present invention. These include, for example, LIPOFECTIN[®] (commercially available cationic liposomes comprising DOTMA and 1,2-dioleoyl-sn-3-phosphoethanolamine ("DOPE"), from GIBCO/BRL, Grand Island, New York, USA); LIPOFECTAMINE[®] (commercially 30 available cationic liposomes comprising N-(1-(2,3-dioleyloxy)propyl)-N-(2-

(sperminecarboxamido)ethyl)-N,N-dimethylammonium trifluoroacetate ("DOSPA") and ("DOPE"), from GIBCO/BRL); and TRANSFECTAM® (commercially available cationic lipids comprising dioctadecylamidoglycyl carboxyspermine ("DOGS") in ethanol from Promega Corp., Madison, Wisconsin, USA).

5 The term "fusogenic" refers to the ability of a liposome or other drug delivery system to fuse with membranes of a cell. The membranes can be either the plasma membrane or membranes surrounding organelles, *e.g.*, endosome, nucleus, *etc.* "Fusogenesis" is the fusion of a liposome to such a membrane.

10 The term "dendrimer" includes reference to branched polymers which possess multiple generations. In dendrimers, each generation creates multiple branch points.

15 The term "ligand" includes any molecule, compound or device with a reactive functional group and includes lipids, amphipathic lipids, carrier compounds, bioaffinity compounds, biomaterials, biopolymers, biomedical devices, analytically detectable compounds, therapeutically active compounds, enzymes, peptides, proteins, immune stimulators, radiolabels, fluorogens, biotin, drugs, haptens, DNA, RNA, polysaccharides, liposomes, virosomes, micelles, immunoglobulins, functional groups or toxins. The foregoing list is not intended to be exhaustive.

20 As used herein, the term "alkyl" denotes branched or unbranched hydrocarbon chains, such as, methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *iso*-butyl, *tert*butyl, octa-decyl and 2-methylpentyl. These groups can be optionally substituted with one or more functional groups which are attached commonly to such chains, such as, hydroxyl, bromo, fluoro, chloro, iodo, mercapto or thio, cyano, alkylthio, heterocycll, aryl, heteroaryl, carboxyl, carbalkoyl, alkyl, alkenyl, nitro, amino, alkoxy, amido, and the like to form alkyl groups such as trifluoromethyl, 3-hydroxyhexyl, 2-carboxypropyl, 2-fluoroethyl, carboxymethyl, cyanobutyl and the like.

25 The term "alkylene" refers to a divalent alkyl as defined above, such as methylene (-CH₂-), propylene (-CH₂CH₂CH₂-), chloroethylene (-CHClCH₂-), 2-thiobutene -CH₂CH(SH)CH₂CH₂, 1-bromo-3-hydroxyl-4-methylpentene (-CHBrCH₂CH(OH)CH(CH₃)CH₂-), and the like.

30 The term "alkenyl" denotes branched or unbranched hydrocarbon chains containing one or more carbon-carbon double bonds.

The term "alkynyl" refers to branched or unbranched hydrocarbon chains containing one or more carbon-carbon triple bonds.

The term "aryl" denotes a chain of carbon atoms which form at least one aromatic ring having preferably between about 6-14 carbon atoms, such as phenyl,

5 naphthyl, indenyl, and the like, and which may be substituted with one or more functional groups which are attached commonly to such chains, such as hydroxyl, bromo, fluoro, chloro, iodo, mercapto or thio, cyano, cyanoamido, alkylthio, heterocycle, aryl, heteroaryl, carboxyl, carbalkoyl, alkyl, alkenyl, nitro, amino, alkoxy, amido, and the like to form aryl groups such as biphenyl, iodoxybiphenyl, methoxybiphenyl, anthryl, bromophenyl, iodophenyl, chlorophenyl, hydroxyphenyl, methoxyphenyl, formylphenyl, acetylphenyl, trifluoromethylthiophenyl, trifluoromethoxyphenyl, alkylthiophenyl, trialkylammoniumphenyl, amidophenyl, thiazolylphenyl, oxazolylphenyl, imidazolylphenyl, imidazolylmethylphenyl, and the like.

10 The term "acyl" denotes the -C(O)R group, wherein R is alkyl or aryl as defined above, such as formyl, acetyl, propionyl, or butyryl.

15 The term "ethoxyacetyl" denotes -C(O)CH₂COCH₂CH₃.

The term "alkoxy" denotes -OR-, wherein R is alkyl.

20 The term "amido" denotes an amide linkage: -C(O)NR- (wherein R is hydrogen or alkyl).

25 The term "amino" denotes an amine linkage: -NR-, wherein R is hydrogen or alkyl.

The term "carboxyl" denotes -C(O)O-, and the term "carbonyl" denotes -C(O)-.

30 The term "carbonate" indicates -OC(O)O-.


25 The term "carbamate" denotes -NHC(O)O-, and the term "urea" denotes -NHC(O)NH-.

The term "phosphoro" denotes -OP(O)(OH)O-.

The term "azido" denotes -N₃.


35 The term "side chain" of amino acids denotes the R group bonded to the α -carbon of naturally-occurring amino acids as well as synthetic amino acids and/or or amino acid mimetics. This group includes, but is not limited to, hydrogen (glycine); methyl (alanine); isopropyl (valine); isobutyl (leucine); *sec*butyl (isoleucine); hydroxymethyl (serine); benzyl (phenylalanine); and the like.

The term "diacylglycerolyl" denotes 2-fatty acyl chains, R¹ and R² having independently between 2 and 30 carbons bonded to the 1- and 2-position of glycerol by ester linkages. The acyl groups can be saturated or have varying degrees of unsaturation. Diacylglycerolyls have the following general formula:




5

The term "dialkylglycerolyl" denotes two C₁-C₃₀ alkyl chains bonded to the 1- and 2-position of glycerol by ether linkages. Dialkylglycerolyls have the following general formula:




10


The term "N-N-dialkylamino" denotes



The term "1,2-diacyloxy-3-aminopropane" denotes 2-fatty acyl chains C₁-C₃₀ bonded to the 1- and 2-position of propane by an ester linkage. The acyl groups can be saturated or have varying degrees of unsaturation. The 3-position of the propane molecule has a -NH- group attached. 1,2-diacyloxy-3-aminopropanes have the following general formula:




The term "1,2-dialkyl-3-aminopropane" denotes 2-alkyl chains (C_1-C_{30}) bonded to the 1- and 2-position of propane by an ether linkage. The 3-position of the propane molecule has a -NH- group attached. 1,2-dialkyl-3-aminopropanes have the following general formula:



**DETAILED DESCRIPTION OF THE INVENTION
AND PREFERRED EMBODIMENTS**

A. Compounds and Oligomer Synthesis


5 The present invention relates to an intrinsically heterobifunctional polyamide oligomer (PAO) of Formula I:



(I)

wherein: R, R¹, R², R³, m, p, q and n have been previously defined.

Polyamide oligomers of Formula I can be prepared by the repeated dimerization of suitable monomers having the following general formula:



10

(IA)

15

wherein: R is NH₂, NR⁴R⁵ (wherein R⁴ and R⁵ may be the same or different and are selected from group consisting of hydrogen, alkyl, acyl or any protecting group for an amino function), N₃, NO₂, CN or any other functional group which can be reduced to an amino function; R² is hydrogen, optionally substituted alkyl, optionally substituted aryl or the side chain of any natural or synthetic amino acid or amino acid mimetic; m is 2 to 6; p is 1 to 4; q is 0 or 1; and R³ is hydroxy or alkoxy.

Examples of suitable amino protecting groups are well known to those skilled in the art and include those described in Greene, W., *et al.*, *Protective Groups in Organic Synthesis*, 2nd Edition (1991), Wiley Interscience, New York.

One preferred embodiment of a monomeric compound of Formula IA is the embodiment wherein m is 4, p is 1, q is 0, R is N₃ and R³ is OCH₂CH₃. This monomer can be activated for dimerization either by deprotection of the acyl group in which case basic hydrolysis yields the analogue in which R³ is OH or, alternatively, by reduction of the N₃ group to a NH₂ group under conditions which do not favor hydrolysis of R³. Suitable conditions are well known to those skilled in the art (see, e.g., Hudlicky, M. (1996) *Reductions in Organic Chemistry*, 2nd Edition, American Chemical Society, Washington, 100, the teachings of which are incorporated herein by reference). In a presently preferred embodiment, the reduction is effected by treatment of the azide with palladium-carbon in the presence of formic acid. Suitably deprotected monomers with complementary reactivity can then be dimerized to form an amide bond using methods which are commonly applied to the formation of peptides and are well known to those skilled in the art (see, e.g., Bodansky, M., et al., *Principles of Peptide Synthesis*, 2nd Edition (1993), Springer-Verlag Inc., New York, the teachings of which are incorporated herein by reference). In a preferred embodiment, this dimerization is performed by first activating the free acid in which R is N₃ and R³ is OH using N-hydroxysuccinimide (NHS) and N,N-dicyclohexylcarbodiimide (DCC), and then adding the free base in which R is NH₂ and R³ is OEt in the presence of triethylamine. The dimerized material thus prepared can then be used as one of the precursors in a subsequent dimerization using the same methods as described above. It will be readily apparent to those skilled in the art that repetition of this dimerization procedure using suitable precursors can be used to assemble a wide range of possible oligomers. In one preferred embodiment, monomers of Formula IA, in which m is 4, p is 1, q is 0, R is N₃ and R³ is OEt, are subjected to three dimerization cycles (see, Figure 2) to produce the octamer of Formula I, wherein n is 8, m is 4, p is 1, q is 0, R¹ is hydrogen, R is N₃ and R³ is OEt for all of the monomeric units. Again, however, it will be readily apparent to those of skill in the art that the values of m, p and q and the definitions of R¹ and R² can vary from monomer to monomer for any given value of "n" monomers.

In yet another preferred embodiment, a monomer of Formula IA, in which m is 4, p is 1, q is 0, R is NHtBOC (tBOC = *tert*-butoxycarbonyl) and R³ is OEt, can be employed in forming the oligomers of Formula I. In this embodiment, deprotection of the amine is effected by treatment with trifluoroacetic acid. Dimerization is then effected as described above. It will be clear to those skilled in the art that a great many

latent amines, protected amines or protected carboxylic acid groups can be utilized for the generation of suitable monomers and still remain within the orbit of the invention.

Monomers of Formula IA can be prepared from oligo-ethyleneglycols in a number of ways which will be readily apparent to those skilled in the art.

5 Oligo-ethyleneglycols ranging from diethylene glycol to hexaethylene glycol are available commercially. Higher order oligo-ethyleneglycols can be synthesized by methods known in the art (see, e.g., Keegstra, et al., *Journal of Organic Chemistry*, 57:6678 (1992)).

10 In a preferred embodiment, tetraethylene glycol is used as the precursor as illustrated in Figure 1. Tetraethylene glycol (TEG) is treated with one half equivalent of dihydropyran and the mono-protected TEG (TEG-mTHP) is isolated. The TEG-mTHP is then treated with an excess of sodium, followed by ethyl bromoacetate. Deprotection of the tetrahydropyran group is effected by treatment with pyridinyl *p*-toluenesulfonate salt in ethanol. Treatment of the product with methane sulfonyl chloride, followed by sodium azide or a suitable latent amino reagent, such as potassium phthalimide or 15 ammonia, generates a suitable monomer. Protection or deprotection of the amino or carboxyl groups may be required. It will be readily apparent to those skilled in the art that this strategy can be used with a wide range of protecting groups, activating agents and alkylating agents without departing from the scope of the invention. Some specific examples of these methods are described in PCT Publication WO 92/01474, the teachings 20 of which are incorporated herein by reference.


In another embodiment, a large excess of TEG can be treated directly with sodium, followed by ethyl bromoacetate. Subsequent manipulation would proceed by treatment with methane sulfonyl chloride, followed by methods as discussed above.

25 In more general embodiments, it may be desirable to include " α -amino acids" as crosslinkers between some or all of the monomeric units of the oligomers of the present invention. This embodiment corresponds to a compound of Formula I, wherein q is 1 for some or all of the monomers for any given value of "n" monomers. Suitable amino acids include all known naturally-occurring amino acids, as well as other amino acids and amino acid mimetics which have been prepared synthetically.

30 It will be immediately apparent to those skilled in the art that the versatility of the present method allows amide bond formation to take place with monomers having varying amounts of ethylene glycol units. Although the foregoing example has been described with the synthesis of TEG units, synthesis of molecules


having varying numbers of ethylene glycol units on either side of an amide bond is possible, *i.e.*, for embodiments of Formula I wherein "m" can have different values in the range of 2 to 6 for all of the monomeric units for any given value of "n" monomers.

5 An alternative embodiment of this invention relates to PAO oligomers of Formula III:




wherein: R is hydrogen, alkyl or aryl; R¹ and R² are independently selected and are hydrogen or alkyl; R⁶ and R⁷ are independently selected and are hydrogen, optionally substituted alkyl or optionally substituted aryl, wherein the substituents include aryl, 10 amino, carboxyl, thiol or hydroxy groups or the side chain of any natural or synthetic amino acid or amino acid mimetic; R³ is halogen, hydrogen, alkoxy, mercapto, hydrazino, amino or NR⁴R⁵, wherein R⁴ and R⁵ are independently hydrogen or alkyl. Alternatively, R, R¹ and the nitrogen to which they are bound form an azido moiety. The index "v" is an integer having a value ranging from 2 to 40; the indexes "m" and 15 "r" are independently selected and have values ranging from 2 to 6; the indexes "x" and "s" are independently selected and have values ranging from 1 to 4; z and t are independently 0 or 1. The parenthesis between R and R³ define a monomeric unit. As described above, R¹, m, R⁶, z, x, r, R⁷ and t can be the same or different throughout the series "v" of monomers.

20 One approach to the synthesis of PAO of Formula III involves the mono-protection of a hydrophilic diamine and diacid with subsequent condensation. The diamine is a compound of Formula IIIA,



(IIIA)

wherein: the index "n" has a value ranging from 2 to 6, and the diacid is a compound of Formula IIIB:



(IIIB)

wherein: the index "n" has a value ranging from 2 to 6, and the indexes "m" and "p" are independently selected and have values ranging from 1 to 4. Condensation of the unprotected amino and carboxylic acid groups form an amide bond.

Although the range of values of m in Figure IA and n in Figures IIIA and IIIB are from about 2 to about 6, it will be apparent to those skilled in the art that smaller or larger values of m and n will be acceptable provided the molecules retain their chemical and physical properties.

Procedures for the formation of amide bonds are well known in the art (see, e.g., Bodansky, M., *et al.*, *Principles of Peptide Synthesis*, 2nd Edition, Springer-Verlag Inc., New York (1993)). By using such procedures, the resulting conjugate has protected amino and carboxylic acid functionalities. Selective deprotection of one or the other of these protective groups generates a suitable precursors for the next dimerization cycle. Many methods have been published for the protection and deprotection of amino and carboxylic acid groups (see, e.g., Greene, W., *et al.*, *Protective Groups in Organic Synthesis*, 2nd Edition, Wiley Interscience, New York (1991)). The mono-protected monomers are prepared by treating the monomer with a 1:1 mole ratio of a protecting agent. This process will generate a mixture of unprotected, mono-protected and di-protected monomers. The mono-protected monomer can then be isolated by conventional procedures known to those skilled in the art. Another method for producing a mono-protected monomer involves the selective introduction of a latent amine or carboxyl group. Such functional groups can then be converted to the amine or carboxylic acid groups by chemical means. Examples are azido (see, Bertozzi, *et. al.*, *Journal of Organic Chemistry* 56:4326 (1991)) or nitrile


groups in the case of amines, and hydroxy groups in the case of carboxylic acids.

Introduction and chemical conversion of such groups can be achieved using well known methods (see, March, J., *Advanced Organic Chemistry*, 3rd Edition, Wiley Interscience, New York (1985), the teachings of which are incorporated herein by references).

5 The PAOs of this invention also include dendrimers. The branching point can occur at R² in Formulae I, IA and II. In Formulae III and IV, the branch point can occur at R⁶ and R⁷. In dendrimers, each generation creates multiple branch points.

B. Reaction of the Oligomer with a Suitable Ligand(s)

10 In another preferred embodiment of this invention, the polyamide oligomer acts as a heterobifunctional bridge. In this respect, this invention relates to a compound having the general formula:



(III)

wherein: A, R¹, R², B, m, p, q and n have been defined above.

15 The attachment of a covalent ligand(s) (i.e., A or B, or A and B) to the polyamide oligomer is made on at least one side of the compound. Any compound which can react with one side of the PAO can be used as a ligand. Suitable ligands include, but are not limited to, lipids, amphipathic lipids, carrier compounds, bioaffinity compounds, biomaterials, biopolymers, biomedical devices, analytically detectable compounds, therapeutically active compounds, enzymes, peptides, proteins, immune stimulators, radiolabels, fluorogens, biotin, drugs, haptens, DNA, RNA, polysaccharides, liposomes, micelles, immunoglobulins, functional groups or toxins.

20 Antibodies of various classes and subclasses and various specificity can also be used as ligands. Suitable biomaterials include, but are not limited to, stents, catheters and other devices. The PAOs of this invention are suitable replacements for polymers used in other mammalian systems.

25

In one preferred embodiment, an amphiphilic lipid is covalently attached as ligand B. In this embodiment, A is a functional group such as hydrogen, alkyl or acyl or other suitable ligand (e.g., a targeting molecule). Suitable amphiphilic lipids which can be covalently attached as ligand B include, but are not limited to, phospholipids with a reactive functionality such as phosphatidylethanolamines (PE), aminolipids, 5 dialkylamines, diacylglycerols, dialkylglycerols, diacyloxypropanamines, dialkyloxypropanamines, and cholesterol. Suitable amphipathic lipids with a reactive functionality can be found among neutral, cationic and non-cationic lipids. Such lipids are preferably amphipathic vesicle-forming or vesicle adopting lipids having two 10 hydrocarbon chains, typically acyl chains and a polar head group. The hydrocarbon chains are typically between 8-22 carbons in length and can be saturated or unsaturated. Hydrocarbon chains having between 14-18 carbons are especially preferred.

Typically, the PAO-lipid conjugates of the present invention are prepared by derivatization of the polar head groups of the phospholipids, such as 15 diacylglycerophospholipids. An example of a diacylglycerophospholipid which can be conjugated to PAO includes, but is not limited to, distearoyl phosphatidylethanolamine (DSPE). The phospholipids usually contain two acyl chains bonded to the 1- and 2- positions of glycerol by ester linkages. Preferably, the PAO is linked to an amino group in the head group of at least one phospholipid species forming a liposome.

20 In one preferred embodiment which is illustrated in Figure 3, N-(ω -N-acetoxy-octa-(14'-amino-3',6',9',12'-tetraoxatetradecanoyl))-1,2-distearoyl-*sn*-glycero-3-phosphoethanolamine (herein referred to as "ATTA8-DPSE") was generated from the octamer using (NHS) and (DCC) to activate the molecule, *i.e.*, the octamer. This activated octamer was then reacted with 1,2-distearoyl-*sn*-glycero-3-phosphoethanolamine 25 to form a new amide bond. The details of this procedure are outlined in Example 1.

Methods known to those of skill in the art can be used for covalent attachment of ligands A and B to the PAO. Suitable linkages include, but are not limited to, amide, amine, carboxyl, carbonate, carbamate, ester and hydrazone bonds. 30 Additional linkages, such as phosphoro and disulfide bonds, can be employed if a cross-linker is used. It will be apparent to those skilled in the art that the ligand(s) to be attached must have a complementary functional group with the PAO. The reaction of these two groups, one on the ligand and the other on the PAO, will provide the desired linkage. For example, when R^3 is hydroxyl and is activated, for instance with NHS and


DCC, to form an active ester, and is then reacted with B which contains an amino group. Where the ligand is a glycosylated protein, such as an antibody, a primary alcohol of the glycosylated protein can be oxidized to form an aldehyde. The aldehyde can then be reacted with the PAO having a hydrazide function ($R^3 = NH_2NH-$) to form the hydrazone (-C=N-NH-).

It may also be desirable to conjugate the A side of the PAO with a ligand. A covalent attachment of a ligand (A) of the compound of Formula II can be generated by complementary reactivity of functional groups, one on the ligand and the other on the PAO. For example, when R and R^1 of Formula I are both hydrogen, thus forming an amine, this functional group can be reacted with a ligand (A) with an activated carboxyl group, such as an acyl chloride or NHS ester, to form an amide. By suitable choice of reactive groups, the desired coupling will be obtained.

A convenient method to attach proteins to a PAO as ligand A is via a carbamate linkage. U.S. Patent No. 5,324,844, incorporated herein by reference, describes the use of the functional group succinidyl carbonate to attach proteins, and this method is also applicable to the compounds described herein.

It will be immediately obvious to a person skilled in the art that conventional peptide chemistry which results in either activation or protection of amino and carboxylic acid groups is applicable herein (see, e.g., Bodansky, M., *et al.*, *Principles of Peptide Synthesis*, 2nd Edition, Springer-Verlag Inc., New York (1993)). By using these conventional procedures, selective protection and activation of either side of the PAO can be accomplished. Subsequent deprotection or activation can then proceed as described above.

Compounds of Formula III can also act as a heterobifunctional bridge. This generates a compound of Formula IV:



wherein: v, m, r, x, s, z, t, R¹, R², R⁶, R⁷, A and B are as defined above. A and B can be covalently attached as described above

C. Liposome Membrane Components

After the PAO-lipid conjugates are prepared, they can be utilized in a variety of ways including, for example, in liposomes, in micelles, in virosomes, in lipid-nucleic acid particles, nucleic acid aggregates and other lipidized drug delivery systems, *i.e.*, compositions, which incorporate or entrap one or more bioactive agents. Such delivery systems are described in greater detail in, for example, the following copending U.S. Patent Applications Serial Numbers 08/454,641, 08/485,458, 08/660,025, 08/484,282, 60/055,094, 08/856,374, 60/053,813 and 60/063,473, entitled "Methods for Encapsulating Nucleic Acids in Lipid Bilayers," filed on October 10, 1997 and bearing Attorney Docket No. 016303-004800, as well as U.S. Patent No. 5,703,055 the teachings all of which are incorporated herein by reference.

The lipid components and PAO-lipid conjugates used in forming the various drug delivery systems will depend, in part, on the type of delivery system employed. For instance, if a liposome is employed, the lipids used in the PAO-lipid conjugate will generally be selected from a variety of vesicle-forming or vesicle adopting lipids, typically including phospholipids and sterols, such as phosphatidylenthanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylglycerol (PG), phosphatidic acid (PA), which has been suitably functionalized, and the like. In contrast, if a micelle is employed, the lipids used in the PAO-lipid conjugate will generally be selected from sterylamines, alkylamines, C₈-C₂₂ alkanoic acids, lysophospholipids, detergents and the like. It will be readily apparent to those of skill in the art that the acyl chains can be varied in length and can be saturated or possess varying degrees of unsaturation. The more saturated the acyl chains the more rigid the membrane. Higher degrees of unsaturation impart more fluidity into the vesicle's membrane. Similarly, the other lipid components (*e.g.*, lipids, cationic lipids, neutral lipids, non-cationic lipids, *etc.*) making up the drug delivery systems of the present invention will vary depending on the drug delivery system employed. Suitable lipids for the various drug delivery systems will be readily apparent to those of skill in the art.

When the drug delivery systems are used to deliver therapeutic genes or oligonucleotides intended to induce or to block production of some protein within the

cell, cationic lipids may be included in the drug delivery system, *e.g.*, liposome, micelle, lipid-nucleic acid particle, *etc.* Nucleic acid is negatively charged and may be combined with a positively charged entity to form a lipid complex suitable for formulation and cellular delivery.

5 Examples of suitable cationic lipids include, but are not limited to, the following: DC-Chol, (*see*, Gao, *et al.*, *Biochem. Biophys. Res. Comm.*, 179:280-285 (1991); DDAB; DMRIE; DODAC, (*see*, commonly owned United States Patent Application Serial Number 08/316,399, filed September 30, 1994, which is incorporated herein by reference); DOGS; DOSPA; DOTAP; and DOTMA. In a presently preferred embodiment, *N,N*-dioleoyl-*N,N*-dimethylammonium chloride is used in combination with a phosphatidylethanolamine.

10 15 In addition, other cationic lipids useful in producing lipid-based carriers for gene and oligonucleotide delivery are LIPOFECTIN (US Patents Nos. 4,897,355; 4,946,787; and 5,208,036 by Eppstein, *et al.*) and LIPOFECTACE (US Patent No. 5,279,883 by Rose). Both agents, as well as other transfecting cationic lipids, are available from Life Technologies, Inc. in Gaithersburg, Maryland.

20 It will be apparent to those skilled in the art that it is possible and often advantageous to use a mixture of at least two polyamide oligomers molecular weights *i.e.*, sizes. For example, in Formula I, it is possible to vary the amount of ethylene oxide (the value of m may vary from 2-6) to generate a distribution of short and long chain polyamide oligomers. The amount of each polyamide oligomer can be added to arrive at an exact ratio of each polyamide oligomer in the mixture of oligomers. For example, by controlling the distribution, it is possible to vary the properties of the drug delivery systems of the present invention (*e.g.*, the fusogenic properties of liposomes).

25 30 In one embodiment of the present invention, a fusogenic liposome or virosome is provided. It will be readily apparent to those of skill in the art that the PAO-lipid conjugates of the present invention can advantageously be incorporated into various types of fusogenic liposomes and virosomes. Such fusogenic liposomes and virosomes can be designed to become fusogenic at the disease or target site. Those of skill in the art will readily appreciate that a number of variables can be used to control when the liposome or virosome becomes fusogenic. Such variables include, for example, the composition of the liposome or virosome, pH, temperature, enzymes, cofactors, ions, *etc.*

In one embodiment, the fusogenic liposome comprises: a lipid capable of adopting a non-lamellar phase, yet capable of assuming a bilayer structure in the presence of a PAO-lipid conjugate; and a PAO-lipid conjugate reversibly associated with the lipid to stabilize the lipid in a bilayer structure. In a presently preferred 5 embodiment, the fusogenic liposome is made up of DOPE and a PAO-PE conjugate. Such fusogenic liposomes are advantageous because the rate at which they become fusogenic can be not only predetermined, but varied as required over a time scale of a few minutes to several tens of hours. It has been found, for example, that by controlling the composition and concentration of the PAO-lipid conjugate, one can control the rate at 10 which the PAO-lipid exchanges out of the liposome *in vivo* and, in turn, the rate at which the liposome becomes fusogenic (see, US Application Serial No. 08/485,608). For instance, it has been found that by controlling the length of the lipid acyl chain(s), one can control the rate at which the PAO-lipid exchanges out of the liposome *in vivo* and, in turn, the rate at which the liposome becomes fusogenic. In particular, it has 15 been discovered that shorter acyl chains (e.g., C-8) exchange out of the liposome more rapidly than longer acyl chains (e.g., C-20). Alternatively, by controlling the composition and concentration of the PAO-lipid conjugate, one can control the rate at which the PAO-lipid is degraded, *i.e.*, broken down, by endogenous systems, *e.g.*, endogenous enzymes in the serum, and, in turn, the rate at which the liposome becomes 20 fusogenic.

The polymorphic behavior of lipids in organized assemblies can be explained qualitatively in terms of the dynamic molecular shape concept (see, Cullis, *et al.*, in "Membrane Fusion" (Wilschut, J. and D. Hoekstra (eds.), Marcel Dekker, Inc., New York, (1991)). When the effective cross-sectional areas of the polar head group 25 and the hydrophobic region buried within the membrane are similar then the lipids have a cylindrical shape and tend to adopt a bilayer conformation. Cone-shaped lipids which have polar head groups that are small relative to the hydrophobic component, such as unsaturated phosphatidylethanolamines, prefer non-bilayer phases such as inverted micelles or inverse hexagonal phase (H_{Π}). Lipids with head groups that are large 30 relative to their hydrophobic domain, such as lysophospholipids, have an inverted cone shape and tend to form micelles in aqueous solution. The phase preference of a mixed lipid system depends, therefore, on the contributions of all the components to the net dynamic molecular shape. As such, a combination of cone-shaped and inverted

cone-shaped lipids can adopt a bilayer conformation under conditions where either lipid in isolation cannot (see, Madden and Cullis, *Biochim. Biophys. Acta*, 684:149-153 (1982)).

A more formalized model is based on the intrinsic curvature hypothesis (see, e.g., Kirk, *et al.*, *Biochemistry*, 23:1093-1102 (1984)). This model explains phospholipid polymorphism in terms of two opposing forces. The natural tendency of a lipid monolayer to curl and adopt its intrinsic or equilibrium radius of curvature (R_o) which results in an elastically relaxed monolayer is opposed by the hydrocarbon packing constraints that result. Factors that decrease the intrinsic radius of curvature, such as increased volume occupied by the hydrocarbon chains when double bonds are introduced, tend to promote H_{II} phase formation. Conversely, an increase in the size of the headgroup increases R_o and promotes bilayer formation or stabilization. Introduction of apolar lipids that can fill the voids between inverted lipid cylinders also promotes H_{II} phase formation (see, Gruner, *et al.*, *Proc. Natl. Acad. Sci. USA*, 82:3665-3669 (1989); Sjoland, *et al.*, *Biochemistry*, 28:1323-1329 (1989)).

As such, in one embodiment, the lipids which can be used to form the fusogenic liposomes of the present invention are those which adopt a non-lamellar phase under physiological conditions or under specific physiological conditions, e.g., in the presence of calcium ions, but which are capable of assuming a bilayer structure in the presence of a PAO-lipid derivative. Such lipids include, but are not limited to, phosphatidylserines, ceramides, glycolipids, or mixtures thereof. Other lipids known to those of skill in the art to adopt a non-lamellar phase under physiological conditions can also be used. Moreover, it will be readily apparent to those of skill in the art that other lipids can be induced to adopt a non-lamellar phase by various non-physiological changes including, for example, changes in pH or ion concentration (e.g., in the presence of calcium ions) and, thus, they can also be used to form the fusogenic liposomes of the present invention. In a presently preferred embodiment, the fusogenic liposome is prepared from a phosphatidylethanolamine. The phosphatidylethanolamine can be saturated or unsaturated. In a presently preferred embodiment, the phosphatidylethanolamine is unsaturated. In an equally preferred embodiment, the fusogenic liposome is prepared from a mixture of a phosphatidylethanolamine (saturated or unsaturated) and a phosphatidylserine. In another equally preferred embodiment, the

fusogenic liposome is prepared from a mixture of a phosphatidylethanolamine (saturated or unsaturated) and a cationic lipid.

In accordance with the present invention, lipids adopting a non-lamellar phase under physiological conditions can be stabilized in a bilayer structure by PAO-lipids which are either bilayer forming themselves, or which are of a complementary dynamic shape. The non-bilayer forming lipid is stabilized in the bilayer structure only when it is associated with, *i.e.*, in the presence of, the PAO-lipid. In selecting an appropriate PAO-lipid conjugate, it is preferable that the PAO-lipid be capable of transferring out of the liposome, or of being chemically modified by endogenous systems such that, with time, it loses its ability to stabilize the lipid in a bilayer structure. Only when liposomal stability is lost or decreased can fusion of the liposome with the plasma membrane of the target cell occur. The PAO-lipid, therefore, is "reversibly associated" with the lipid and only when it is associated with the lipid is the lipid constrained to adopt the bilayer structure under conditions where it would otherwise adopt a non-lamellar phase. As such, the PAO-lipids of the present invention are capable of stabilizing the lipid in a bilayer structure, yet they are capable of exchanging out of the liposome, or of being chemically modified by endogenous systems so that, with time, they lose their ability to stabilize the lipid in a bilayer structure, thereby allowing the liposome to become fusogenic.

Typically, the PAO-lipid conjugate is present at a concentration ranging from about 0.05 mole percent to about 50 mole percent. In a presently preferred embodiment, the PAO-lipid conjugate is present at a concentration ranging from 0.05 mole percent to about 25 mole percent. In an even more preferred embodiment, the PAO-lipid conjugate is present at a concentration ranging from 0.05 mole percent to about 15 mole percent. One of ordinary skill in the art will appreciate that the concentration of the PAO-lipid conjugate can be varied depending on the PAO-lipid conjugate employed and the rate at which the liposome is to become fusogenic.

By controlling the composition and concentration of the PAO-lipid conjugate, one can control the rate at which the PAO-lipid conjugate exchanges out of the liposome and, in turn, the rate at which the liposome becomes fusogenic. For instance, when a PAO-phosphatidylethanolamine conjugate or a PAO-ceramide conjugate is used as the bilayer stabilizing component, the rate at which the liposome becomes fusogenic can be varied, for example, by varying the concentration of the PAO-lipid

conjugate, by varying the molecular weight or composition of the PAO, or by varying the chain length and degree of saturation of the acyl chain groups on the phosphatidylethanolamine or the ceramide. In addition, other variables including, for example, pH, temperature, ionic strength, *etc.* can be used to vary and/or control the 5 rate at which the liposome becomes fusogenic. Other methods which can be used to control the rate at which the liposome becomes fusogenic will become apparent to those of skill in the art upon reading this disclosure.

10 In one preferred embodiment of the present invention, the liposomes contain cholesterol. It has been determined that when cholesterol-free liposomes are used *in vivo*, they have a tendency to absorb cholesterol from the plasma lipoproteins and cell membranes. Cholesterol, if included, is generally present at a concentration ranging from 0.2 mole percent to about 50 mole percent and, more preferably, at a concentration ranging from about 35 mole percent to about 45 mole percent.

D. Liposome Preparation

15 A variety of methods are available for preparing liposomes as described in, *e.g.*, Szoka, *et al.*, *Ann. Rev. Biophys. Bioeng.*, 9:467 (1980), U.S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, 4,946,787, PCT Publication No. WO 91/17424, Deamer and Bangham, *Biochim. Biophys. Acta*, 443:629-634 (1976); Fraley, *et al.*, *Proc. Natl. Acad. Sci. USA*, 76:3348-3352 (1979); Hope, *et al.*, *Biochim. Biophys. Acta*, 812:55-65 (1985); Mayer, *et al.*, *Biochim. Biophys. Acta*, 858:161-168 (1986); Williams, *et al.*, *Proc. Natl. Acad. Sci.*, 85:242-246 (1988), the text *Liposomes*, Marc J. Ostro, ed., Marcel Dekker, Inc., New York, 1983, Chapter 1, and Hope, *et al.*, *Chem. Phys. Lip.*, 40:89 (1986), all of which are incorporated herein by reference. Suitable methods include, but are not limited to, sonication, extrusion, high pressure/homogenization, microfluidization, 20 detergent dialysis, calcium-induced fusion of small liposome vesicles, and ether-infusion methods, all of which are well known in the art. One method produces multilamellar vesicles of heterogeneous sizes. In this method, the vesicle-forming lipids are dissolved in a suitable organic solvent or solvent system and dried under vacuum or an inert gas to 25 form a thin lipid film. If desired, the film may be redissolved in a suitable solvent, such as tertiary butanol, and then lyophilized to form a more homogeneous lipid mixture 30 which is in a more easily hydrated powder-like form. This film is covered with an

aqueous buffered solution and allowed to hydrate, typically over a 15-60 minute period with agitation. The size distribution of the resulting multilamellar vesicles can be shifted toward smaller sizes by hydrating the lipids under more vigorous agitation conditions or by adding solubilizing detergents, such as deoxycholate.

5 Unilamellar vesicles are generally prepared by sonication or extrusion. Sonication is generally performed with a tip sonifier, such as a Branson tip sonifier, in an ice bath. Typically, the suspension is subjected to several sonication cycles. Extrusion may be carried out by biomembrane extruders, such as the Lipex Biomembrane Extruder. Defined pore size in the extrusion filters may generate 10 unilamellar liposomal vesicles of specific sizes. The liposomes may also be formed by extrusion through an asymmetric ceramic filter, such as a Ceraflow Microfilter, commercially available from the Norton Company, Worcester MA.

15 Following liposome preparation, the liposomes which have not been sized during formation may be sized to achieve a desired size range and relatively narrow distribution of liposome sizes. A size range of about 0.2-0.4 microns allows the liposome suspension to be sterilized by filtration through a conventional filter. The filter sterilization method can be carried out on a high through-put basis if the liposomes have been sized down to about 0.2-0.4 microns.

20 Several techniques are available for sizing liposomes to a desired size. One sizing method is described in U.S. Pat. No. 4,737,323, incorporated herein by reference. Sonicating a liposome suspension either by bath or probe sonication produces a progressive size reduction down to small unilamellar vesicles less than about 0.05 microns in size. Homogenization is another method which relies on shearing energy to fragment large liposomes into smaller ones. In a typical homogenization procedure, 25 multilamellar vesicles are recirculated through a standard emulsion homogenizer until selected liposome sizes, typically between about 0.1 and 0.5 microns, are observed. The size of the liposomal vesicles may be determined by quasi-electric light scattering (QELS) as described in Bloomfield, *Ann. Rev. Biophys. Bioeng.*, 10:421-450 (1981), incorporated herein by reference. Average liposome diameter may be reduced by 30 sonication of formed liposomes. Intermittent sonication cycles may be alternated with QELS assessment to guide efficient liposome synthesis.

Extrusion of liposome through a small-pore polycarbonate membrane or an asymmetric ceramic membrane is also an effective method for reducing liposome sizes to

5 a relatively well-defined size distribution. Typically, the suspension is cycled through the membrane one or more times until the desired liposome size distribution is achieved. The liposomes may be extruded through successively smaller-pore membranes, to achieve gradual reduction in liposome size. For use in the present invention, liposomes having a size ranging from about 0.05 microns to about 0.40 microns are preferred.

E. Use of Liposomes as Drug Delivery Vehicles

10 The drug delivery compositions of the present invention (e.g., liposomes, micelles, lipid-nucleic acid particles, virosomes, *etc.*) are useful for the systemic or local delivery of therapeutic agents or bioactive agents and are also useful in diagnostic assays. Such delivery systems are described in greater detail in, for example, the following 15 copending U.S. Patent Applications Serial Numbers 08/454,641, 08/485,458, 08/660,025, 08/484,282, 60/055,094, 08/856,374, 60/053,813 and 60/063,473, entitled "Methods for Encapsulating Nucleic Acids in Lipid Bilayers," filed on October 10, 1997 and bearing Attorney Docket No. 016303-004800, the teachings of all of which are incorporated herein by reference.

The following discussion refers generally to liposomes; however, it will be readily apparent to those of skill in the art that this same discussion is fully applicable to the other drug delivery systems of the present invention (e.g., micelles, virosomes, lipid-nucleic acid particles, *etc.*).

20 For the delivery of therapeutic or bioactive agents, the compositions can be loaded with a therapeutic agent and administered to the subject requiring treatment. The therapeutic agents which are administered using the present invention can be any of a variety of drugs which are selected to be an appropriate treatment for the disease to be treated. Often the drug will be an antineoplastic agent, such as vincristine, doxorubicin, mitoxantrone, camptothecin, cisplatin, bleomycin, cyclophosphamide, methotrexate, 25 streptozotocin, and the like. Especially preferred antitumor agents include, for example, actinomycin D, vincristine, vinblastine, cystine arabinoside, anthracyclines, alkylative agents, platinum compounds, antimetabolites, and nucleoside analogs, such as methotrexate and purine and pyrimidine analogs. It may also be desirable to deliver anti-infective agents to specific tissues by the present methods. The compositions of the 30 present invention can also be used for the selective delivery of other drugs including, but not limited to, local anesthetics, *e.g.*, dibucaine and chlorpromazine; beta-adrenergic

blockers, *e.g.*, propranolol, timolol and labetolol; antihypertensive agents, *e.g.*, clonidine and hydralazine; anti-depressants, *e.g.*, imipramine, amitriptyline and doxepim; anti-conversants, *e.g.*, phenytoin; antihistamines, *e.g.*, diphenhydramine, chlorpheniramine and promethazine; antibiotic/antibacterial agents, *e.g.*, gentamycin, ciprofloxacin, and cefoxitin; antifungal agents, *e.g.*, miconazole, terconazole, econazole, isoconazole, butaconazole, clotrimazole, itraconazole, nystatin, naftifine and amphotericin B; antiparasitic agents, hormones, hormone antagonists, immunomodulators, neurotransmitter antagonists, antiglaucoma agents, vitamins, narcotics, and imaging agents.

10 As mentioned above, cationic lipids can be used in the delivery of therapeutic genes or oligonucleotides intended to induce or to block production of some protein within the cell. Nucleic acid is negatively charged and may be combined with a positively charged entity to form a lipid complex suitable for formulation and cellular delivery.

15 Particularly useful antisense oligonucleotides are directed to targets such as c-myc, bcr-abl, c-myb, ICAM-1, C-erb B-2 and BCL-2.

The PAO-lipid conjugates of the present invention are also useful in the delivery of peptides, nucleic acids, plasmid DNA, minichromosomes and ribozymes.

20 Another clinical application of PAO-lipid conjugates of this invention is as an adjuvant for immunization of both animals and humans. Protein antigens, such as diphtheria toxoid, cholera toxin, parasitic antigens, viral antigens, immunoglobulins, enzymes and histocompatibility antigens, can be incorporated into or attached onto the liposomes containing the PAO-lipid conjugates of the present invention for immunization purposes.

25 Liposomes containing the PAO-lipid conjugates of the present invention are also particularly useful as carriers for vaccines that will be targeted to the appropriate lymphoid organs to stimulate an immune response.

30 Liposomes containing the PAO-lipid conjugates of the present invention can also be used as a vector to deliver immunosuppressive or immunostimulatory agents selectively to macrophages. In particular, glucocorticoids useful to suppress macrophage activity and lymphokines that activate macrophages can be delivered using the liposomes of the present invention.

Liposomes containing the PAO-lipid conjugates of the present invention and containing targeting molecules can be used to stimulate or suppress a cell. For example, liposomes incorporating a particular antigen can be employed to stimulate the B cell population displaying surface antibody that specifically binds that antigen.

5 Liposomes incorporating growth factors or lymphokines on the liposome surface can be directed to stimulate cells expressing the appropriate receptors for these factors. Using this approach, bone marrow cells can be stimulated to proliferate as part of the treatment of cancer patients.

Liposome-encapsulated antibodies can be used to treat drug overdoses. 10 The tendency of liposomes having encapsulated antibodies to be delivered to the liver has a therapeutic advantage in clearing substances, such as toxic agents, from the blood circulation. It has been demonstrated that whereas unencapsulated antibodies to digoxin caused intravascular retention of the drug, encapsulated antibodies caused increased splenic and hepatic uptake and an increased excretion rate of digoxin.

15 Liposomes containing the PAO-lipid conjugates of this invention also find utility as carriers for introducing lipid or protein antigens into the plasma membrane of cells that lack the antigens. For example, histocompatibility antigens or viral antigens can be introduced into the surface of viral infected or tumor cells to promote recognition and killing of these cells by the immune system.

20 In addition, liposomes containing the PAO-lipid conjugates of the present invention can be used to deliver any product (e.g., therapeutic agents, diagnostic agents, labels or other compounds) including those currently formulated in PEG-derivatized liposomes.

25 In certain embodiments, it is desirable to target the liposomes of this invention using targeting moieties that are specific to a cell type or tissue. Targeting of liposomes using a variety of targeting moieties, such as ligands, cell surface receptors, glycoproteins, vitamins (e.g., riboflavin) and monoclonal antibodies, has been previously described (see, e.g., U.S. Pat. Nos. 4,957,773 and 4,603,044, the teachings of which are incorporated herein by reference). The targeting moieties can comprise the entire protein or fragments thereof.

30 Targeting mechanisms generally require that the targeting agents be positioned on the surface of the liposome in such a manner that the target moiety is available for interaction with the target, for example, a cell surface receptor. The

liposome is designed to incorporate a connector portion into the membrane at the time of liposome formation. The connector portion must have a lipophilic portion that is firmly embedded and anchored into the membrane. It must also have a hydrophilic portion that is chemically available on the aqueous surface of the liposome. The hydrophilic portion is selected so as to be chemically suitable with the targeting agent, such that the portion and agent form a stable chemical bond. Therefore, the connector portion usually extends out from the liposome's surface and is configured to correctly position the targeting agent. In some cases, it is possible to attach the target agent directly to the connector portion, but in many instances, it is more suitable to use a third molecule to act as a "molecular bridge." The bridge links the connector portion and the target agent off of the surface of the liposome, thereby making the target agent freely available for interaction with the cellular target.

Standard methods for coupling the target agents can be used. For example, phosphatidylethanolamine, which can be activated for attachment of target agents, or derivatized lipophilic compounds, such as lipid-derivatized bleomycin, can be used. Antibody-targeted liposomes can be constructed using, for instance, liposomes that incorporate protein A (see, Renneisen, *et al.*, *J. Bio. Chem.*, 265:16337-16342 (1990) and Leonetti, *et al.*, *Proc. Natl. Acad. Sci. (USA)*, 87:2448-2451 (1990). Other examples of antibody conjugation are disclosed in U.S. Patent Application Number 08/316,394, filed September 30, 1994, the teachings of which are incorporated herein by reference. Examples of targeting moieties can also include other proteins, specific to cellular components, including antigens associated with neoplasms or tumors. Proteins used as targeting moieties can be attached to the liposomes via covalent bonds. See, Heath, *Covalent Attachment of Proteins to Liposomes, 149 Methods in Enzymology* 111-119 (Academic Press, Inc. 1987). Other targeting methods include the biotin-avidin system.

In some cases, the diagnostic targeting of the liposome can subsequently be used to treat the targeted cell or tissue. For example, when a toxin is coupled to a targeted liposome, the toxin can then be effective in destroying the targeted cell, such as a neoplastic cell.

In addition, as described above, one of the advantages of the PAO compounds of the present invention is that they are intrinsically heterobifunctional where each end of the molecule is different. As such, a lipid or other ligand can be conjugated

to one end of the PAO, while an antibody or other targeting moiety can be conjugated to the other end of the PAO. Accordingly, the PAO compounds of the present invention can serve as the "connector portion" or the "molecular bridge" as described above.

Moreover, it will be readily apparent to those of skill in the art that the PAO compounds of the present invention can be conjugated to biomaterials, biopolymers and biomedical devices including, but not limited to, catheters and stents. Other uses for the PAO compounds of the present invention will be readily apparent to those of skill in the art upon a reading of the disclosure.

F. Use of the Liposomes as Diagnostic Agents

The drug delivery compositions, *e.g.*, liposomes, prepared using the PAO-lipids of this invention can be labeled with markers that will facilitate diagnostic imaging of various disease states including tumors, inflamed joints, lesions, *etc.* Typically, these labels will be radioactive markers, although fluorescent labels can also be used. The use of gamma-emitting radioisotopes is particularly advantageous as they can easily be counted in a scintillation well counter, do not require tissue homogenization prior to counting and can be imaged with gamma cameras.

Gamma- or positron-emitting radioisotopes are typically used, such as ^{99}Tc , ^{24}Na , ^{51}Cr , ^{59}Fe , ^{67}Ga , ^{86}Rb , ^{111}In , ^{125}I , and ^{195}Pt as gamma-emitting; and such as ^{68}Ga , ^{82}Rb , ^{22}Na , ^{75}Br , ^{122}I and ^{18}F as positron-emitting.

The liposomes can also be labelled with a paramagnetic isotope for purposes of *in vivo* diagnosis, as through the use of magnetic resonance imaging (MRI) or electron spin resonance (ESR). *See*, for example, U.S. Pat. No. 4,728,575, the teachings of which are incorporated herein by reference.

G. Loading the Liposomes

Methods of loading conventional drugs into liposomes include, for example, an encapsulation technique, loading into the bilayer and a transmembrane potential loading method.

In one encapsulation technique, the drug and liposome components are dissolved in an organic solvent in which all species are miscible and concentrated to a dry film. A buffer is then added to the dried film and liposomes are formed having the drug incorporated into the vesicle walls. Alternatively, the drug can be placed into a

buffer and added to a dried film of only lipid components. In this manner, the drug will become encapsulated in the aqueous interior of the liposome. The buffer which is used in the formation of the liposomes can be any biologically compatible buffer solution of, for example, isotonic saline, phosphate buffered saline, or other low ionic strength buffers. Generally, the drug will be present in an amount of from about 0.01 ng/mL to about 50 mg/mL. The resulting liposomes with the drug incorporated in the aqueous interior or in the membrane are then optionally sized as described above.

Transmembrane potential loading has been described in detail in U.S. Patent No. 4,885,172, U.S. Patent No. 5,059,421, and U.S. Patent No. 5,171,578, the contents of which are incorporated herein by reference. Briefly, the transmembrane potential loading method can be used with essentially any conventional drug which can exist in a charged state when dissolved in an appropriate aqueous medium. Preferably, the drug will be relatively lipophilic so that it will partition into the liposome membranes. A transmembrane potential is created across the bilayers of the liposomes or protein-liposome complexes and the drug is loaded into the liposome by means of the transmembrane potential. The transmembrane potential is generated by creating a concentration gradient for one or more charged species (e.g., Na^+ , K^+ and/or H^+) across the membranes. This concentration gradient is generated by producing liposomes having different internal and external media and has an associated proton gradient. Drug accumulation can then occur in a manner predicted by the Henderson-Hasselbach equation.

The liposome compositions of the present invention can be administered to a subject according to standard techniques. Preferably, pharmaceutical compositions of the liposome compositions are administered parenterally, i.e., intraperitoneally, intravenously, subcutaneously or intramuscularly. More preferably, the pharmaceutical compositions are administered intravenously by a bolus injection. Suitable formulations for use in the present invention are found in *Remington's Pharmaceutical Sciences*, Mack Publishing Company, Philadelphia, PA, 17th ed. (1985). The pharmaceutical compositions can be used, for example, to diagnose a variety of conditions, or treat a diseased state. The diseases include, but are not limited to, inflammation associated with rheumatoid arthritis, post-ischemic leukocyte-mediated tissue damage (reperfusion injury), acute leukocyte-mediated lung injury (e.g., adult respiratory distress syndrome),

septic shock, and acute and chronic inflammation, including atopic dermatitis and psoriasis. In addition, various neoplasms and tumor metastases can be treated.

Preferably, the pharmaceutical compositions are administered intravenously. Thus, this invention provides compositions for intravenous administration which comprise a solution of the liposomes suspended in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, *e.g.*, water, buffered water, 0.9% isotonic saline, and the like. These compositions can be sterilized by conventional, well known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is or lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, *etc.*


The concentration of liposome compositions in the pharmaceutical formulations can vary widely, *i.e.*, from less than about 0.05%, usually at or at least about 2-5% to as much as 10 to 30% by weight and will be selected primarily by fluid volumes, viscosities, *etc.*, in accordance with the particular mode of administration selected. For diagnosis, the amount of composition administered will depend upon the particular label used (*i.e.*, radiolabel, fluorescence label, and the like), the disease state being diagnosed and the judgement of the clinician, but will generally be between about 1 and about 5 mg per kilogram of body weight.

The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of noncritical parameters which can be changed or modified to yield essentially the same results.

EXAMPLES**EXAMPLE I**


This example illustrates the synthesis of N-(ω -azido-octa-(14'-amino-3',6',9',12'-tetraoxatetradecanoyl))-1,2-distearoyl-sn-glycero-3-phosphoethanolamine 5 ("ATTA-DPSE").

Synthesis of 1-O-tetrahydropyranyl-11-hydroxy-3,6,9-trioxaundecanol 1. Concentrated hydrochloric acid (5 mL) was slowly added to a solution of dihydropyran (215 g) in tetraethylene glycol (600 g). The exothermic reaction was cooled in an ice bath and then stirred overnight at room temperature. The solution was diluted with 10 water (1 L) and neutralized with excess sodium bicarbonate solution until slightly basic. The solution was washed twice with diethyl ether (200 mL). The combined ethereal extracts were washed twice with water (200 mL). The aqueous fractions were washed with diethyl ether (100 mL) and then combined with the original aqueous extract. This extract was then washed four times with methylene chloride. The methylene chloride 15 fractions were combined and washed with water (200 mL), which in turn was washed with methylene chloride. The combined methylene chloride fractions were dried down on a rotovap. Residual water was removed by azeotropic distillation with toluene on a rotovap (four times), yielding 1 as a colorless crude oil (390 g).



20 *Synthesis of ethyl 14-hydroxy-3,6,9,12-tetraoxatetradecanoate 2.* A solution of crude 1 (390 g) in toluene (1 L) was treated with sodium (64 g) in a closed flask vented through a mineral oil bubbler. The mixture was stirred at room temperature for five days and then filtered through glass wool to remove unreacted sodium. Ethyl bromoacetate (100 mL) was added and the mixture refluxed for three hours. The solution was cooled and washed with water (2 x 500 mL). The aqueous phase was washed with methylene chloride (2 x 100 mL). The organic

fractions were combined and the solvent removed on a rotovap. The residue was then dissolved in ethanol (1 L) and treated with pyridinyl *p*-toluenesulfonic acid (30 g) at 60°C for one hour. The solution was diluted with water and washed with ether (2 x 400 mL). The ether fractions were washed with water (100 mL). The combined aqueous fractions were washed with methylene chloride (4x), yielding 180 g of crude 2 after removal of the solvent.



Synthesis of 14-azido-3,6,9,12-tetraoxatetradecanoic acid 3. Triethylamine (81 mL) was slowly added to a stirred solution of crude 2 (110 g) and methane sulfonylchloride (36 mL) in benzene (600 mL). The solution was stirred at room temperature for one hour, diluted with water and acidified with dilute hydrochloric acid. The mixture was extracted with methylene chloride (3x). The solvent was removed on a rotovap. Residual methylene chloride was removed by addition of toluene followed by removal of solvent on a rotovap (3x). The residue was dissolved in ethanol (750 mL).


10 Sodium azide (24 g) was added and the solution refluxed for four hours. Periodic additions of water were made as a gel like precipitate formed to keep most of the material in solution. The mixture was then stirred at room temperature overnight. The mixture was filtered, diluted with water and extracted with methylene chloride (6x). The combined methylene chloride fractions were washed with water, which in turn was washed with methylene chloride (4x). The solvent was removed from the combined methylene chloride fractions using a rotovap. The residue was suspended in a solution of sodium hydroxide (32 g) in water (100 mL) and stirred at 45°C for half an hour. The mixture was diluted with water (200 mL) and extracted with methylene chloride (3 x 100 mL). The methylene chloride fractions were washed with water (2 x 50 mL) and the aqueous fractions combined with the previous aqueous extracts. The combined aqueous fractions were acidified with concentrated hydrochloric acid and extracted with methylene chloride (3 x 100 mL). The solvent was removed from the organic fractions

15


20

25

using a rotovap and the residue dried by addition of ethanol followed by removal of the solvent, yielding 3 as a yellow oil (77 g).



Synthesis of ethyl 14-amino-3,6,9,12-tetraoxatetradecanoate 4. A solution of anhydrous hydrogen chloride in ethanol was prepared by slow addition of acetyl chloride (100 mL) to anhydrous ethanol (500 mL), followed by stirring at room temperature for one hour. 3 (44 g) was added and the solution stirred for one hour. Water (1 L) was added and the solution extracted with methylene chloride (3x). The solvent was removed on a rotovap and the residue dissolved in ethanol. Activated charcoal was added and the mixture stirred for approximately half an hour after which it was filtered through celite. The solvent was then removed on a rotovap. The residue was dissolved in ethanol/water (50:50) (200 mL). Formic acid was added (16 g) followed by 10% palladium/carbon (2.7 g). The solution was warmed to 60°C and stirred until evolution of gas had ceased. The mixture was filtered through celite. The filtrate was neutralized with aqueous sodium bicarbonate until samples diluted with water were neutral (pH ~ 7) by analysis with pH paper. The solvent was then removed on a rotovap. Residual water and salt were removed by filtration and azeotropic distillation with ethanol (2x), yielding crude 4 as a yellow oil (33 g).




20 *Synthesis of ethyl- ω -azido-bis-(14-amino-3,6,9,12-tetraoxatetradecanoate)*

5. A solution of 3 (33 g) in methylene chloride (100 mL) was treated with N-hydroxysuccimide (NHS, 20 g) and N,N-dicyclohexylcarbodiimide (DCC, 27 g dissolved in 300 mL methylene chloride). The solution was stirred for one hour and

filtered. A solution of 4 (33 g) in ethanol (100 mL) was added to the filtrate, followed by triethylamine (20 mL). The reaction mixture was stirred at room temperature for 1 h, filtered and diluted with water. Extraction of the aqueous phase with methylene chloride yielded ~10 g crude 3. The aqueous phase was acidified with dilute hydrochloric acid and extracted with methylene chloride (3x). The solvent was removed on a rotovap and the residue dissolved in water. All residual solvent was removed using the rotovap and the aqueous suspension filtered. The aqueous solution was then extracted with methylene chloride (3x), yielding ~40 g of crude 5 after removal of the solvent. Crude 5 was passed down a silica gel column (300 g SiO_2 , 4-16% $\text{MeOH}/\text{CH}_2\text{Cl}_2$), yielding 16 g of 5.

10 5.



Synthesis of ethyl- ω -azido-tetra-(14-amino-3,6,9,12-tetraoxatetradecanoate)

8. A suspension of 5 (15 g) in a solution of sodium carbonate (15 g) in water (150 mL) was stirred at 45°C until all of the oil had dissolved. The solution was stirred at 45°C for a further half an hour and then extracted with methylene chloride (2x). The solution


15

was acidified (pH=2) with dilute hydrochloric acid and extracted with methylene chloride (3x). Removal of solvent yielded the crude acid 6 (9 g).



5 5 (15 g) was added to an anhydrous solution of hydrogen chloride in ethanol (prepared from 40 mL acetyl chloride and 200 mL ethanol) and stirred at room temperature for two hours. The solution was diluted with water and extracted with methylene chloride (3x). The solvent was removed on a rotovap. The residue was dissolved in ethanol (100 mL) and treated with formic acid (2.4 g) and 10% palladium on carbon (0.7 g, slow addition). The suspension was heated to 60°C until evolution of gas ceased, after which it was filtered through celite. The filtrate contained a crude 10 solution of the amine 7.

15 A solution of 6 (9 g) in methylene chloride (100 mL) was treated with NHS (4.3 g) and DCC (4.0 g) at room temperature for one hour with stirring. The solution was filtered and added slowly to the solution of 7, which had immediately, previously been treated with triethylamine (2 mL). The solution was stirred for half an hour. More triethylamine (3 mL) was added and the solution stirred for a further hour. The mixture was diluted with water, acidified with dilute hydrochloric acid and extracted with methylene chloride (3x). The solvent was removed on a rotovap and the residue taken up in water. The suspension was filtered and extracted with methylene chloride (3x). The combined organic fractions were dried over magnesium sulphate, filtered and 20 the solvent removed. The residue was passed down a silica gel column (200 g SiO₂, 4-16% MeOH/CH₂Cl₂), yielding 8 (9.8 g) as a yellow oil.

42





5



6

7



8

Synthesis of ethyl- ω -azido-octa-(14-amino-3,6,9,12-tetraoxatetradecanoate)


11. A suspension of 8 (4.9 g) in a solution of sodium carbonate (2.5 g) in water (50 mL) was stirred at 45°C until all of the oil had dissolved. The solution was stirred at 45°C for a further half an hour and then extracted with methylene chloride (1x). The solution was acidified (pH=2) with dilute hydrochloric acid and extracted with methylene chloride (3x). Removal of solvent yielded the crude acid 9 (3.86 g).

5


8 (4.9 g) was added to an anhydrous solution of hydrogen chloride in ethanol (prepared from 10 mL acetyl chloride and 50 mL ethanol) and stirred at room temperature for two hours. The solution was diluted with water and extracted with methylene chloride (3x). The solvent was removed on a rotovap. The residue was dissolved in ethanol (100 mL) and treated with formic acid (0.5 g) and 10% palladium on carbon (0.2 g, slow addition). The suspension was heated to 60°C until evolution of gas ceased, after which it was filtered through celite. The filtrate contained a crude solution of the amine 10. TLC analysis showed that all of the starting azide had been converted to a primary amine (flourescamine test positive).

A solution of 9 (3.86 g) in methylene chloride (50 mL) was treated with NHS (0.76 g) and DCC (0.96 g) at room temperature for one hour with stirring. The solution was filtered and added slowly to the solution of 7, which had immediately previously treated with triethylamine (1 mL). The solution was stirred for half an hour. More triethylamine (2 mL) was added and the solution stirred for a further hour. The mixture was diluted with water, acidified with dilute hydrochloric acid and extracted with methylene chloride (3x). The solvent was removed on a rotovap and the residue taken up in water. The suspension was filtered and extracted with methylene chloride (2x). The combined organic fractions were dried over magnesium sulphate, filtered and the solvent removed. The residue (7.6 g) was passed down a silica gel column (200 g SiO₂, 4-16% MeOH/CH₂Cl₂), yielding 11 (3.9 g) as a colorless oil.


44



8



aq. Na_2CO_3




9

10



E₁N



11


Synthesis of N-(ω -azido-octa-(14'-amino-3',6',9',12'-tetraoxatetradecanoyl))-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (ATTA8-DSPE)

5



13. 11 (3.9 g) was hydrolyzed using the protocol outlined for 8, yielding 3.5 g of the crude acid 12. A solution of 12 in chloroform (50 mL) was treated with NHS (0.66 g) and DCC (0.44 g) at room temperature with stirring for one hour. The solution was filtered and treated with DSPE (1.35 g). The suspension was warmed to 60°C until most

of the DSPE had dissolved. Triethylamine (0.5 mL) was added and the solution warmed until all solids had dissolved. The solution was stirred at room temperature for one hour, diluted with water and carefully acidified to pH 5 with dilute hydrochloric acid. The mixture was extracted with methylene chloride (3x). The solvent was removed on a rotovap. The residue was taken up in water, filtered and extracted with methylene chloride. The solvent was removed on a rotovap. The residue was suspended in methanol, centrifuged at 3000 rpm for one hour and the supernatant decanted. The solvent was removed on a rotovap. The residue was then taken up in water, filtered through a 0.22 μ m filter and lyophilized. Column chromatography (100 g SiO₂, 4-100% MeOHCH₂Cl₂), followed by uptake in water and lyophilization, yielded 13 (1.76 g) as a sticky white powder.



46



11



12



13

EXAMPLE II


This example illustrates the synthesis of N-(ω -azido-octa-(14'-amino-3'-6'-9',12'-tetraoxatetradecanoyl))-1,2-dioleoyl-*sn*-glycero-3-phosphoethanolamine.

Synthesis of N-(ω -azido-octa-(14'-amino-3'-6'-9',12'-


*tetraoxatetradecanoyl))-1,2-dioleoyl-*sn*-3-glycero-phosphoethanolamine (ATTA8-DOPE)*

14. 11 (1.2 g) was hydrolyzed as using the protocol outlined for 8 with a solution of aqueous sodium carbonate (0.3 g in 20 mL), yielding 1.1 g of the crude acid 13. A solution of 13 in chloroform (10 mL) was treated with NHS (0.15 g) and DCC (0.16 g) at room temperature with stirring for one hour. The solution was filtered and treated with DOPE (0.32 g). Triethylamine (10 drops) was added. The solution was stirred at room temperature for an hour, diluted with water and carefully acidified to pH 7 with dilute hydrochloric acid. The mixture was extracted with methylene chloride (5x). The solution was dried over anhydrous magnesium sulphate, filtered and the solvent removed on a rotovap. The residue was taken up in water, centrifuged at 3000 rpm for one hour. The supernatant was filtered through a 0.22 μ m filter and lyophilized. Column chromatography (70 g SiO₂, 4-100% MeOH/CH₂Cl₂), followed by uptake in water and lyophilization, yielded 13 (0.3 g) as an oil. An additional 0.8 g of a mixture of 13 and 14 was also recovered but not further purified.


48



11

aq.Na₂CO₃

12

1) NHS/DCC
2) DSPE/Et₃N

14

EXAMPLE III

This example illustrates inhibition of aggregation-disaggregation reactions as shown in Figure 4.

5

Liposome preparation. Liposomes were prepared as described by Hope, *et al.* Briefly, lipid mixtures of the appropriate composition were dissolved in chloroform and concentrated to a homogenous film under a nitrogen stream in a warm water bath.

The film was then dried overnight in a lyophilizer. The dried lipid was hydrated in HBS at 45°C (approximate lipid concentration of 40 mM) and the resultant multilamellar vesicles frozen in liquid nitrogen and thawed at 45°C five times before being extruded through two stacked polycarbonate 100 nm filters (Nucleopore) using an extrusion device (Lipex Biomembranes, Inc., Vancouver, Canada) at 45°C. Lipid concentrations were determined using a phosphate assay, following which the liposomes were diluted with buffer to the desired concentration.

5 *Lipid assay.* Samples with an estimated phosphate content in the range 50-150 nmol were digested in perchloric acid (0.7 mL) at 180°C for one hour. The samples were allowed to cool. Ammonium molybdate solution (7 mL, prepared by dissolving 4.4 g in 2 L of distilled water and 40 mL of sulfuric acid) and Fiske reagent (0.7 mL) were added and the solutions vortexed. The solutions were heated in a boiling water bath for thirty minutes, allowed to cool and assayed relative to a standard curve (0, 50, 100, 200 nmol phosphate) at 815 nm. Phosphate assays were performed in triplicate.

10 *Aggregation-disaggregation assay.* Liposomes comprised of stearylamine/POPC (5:95) and DOPS/POPC (20:80) were prepared in buffer (10 mM hepes, 15 mM NaCl, pH 7.4) and diluted to 1 mM. Aliquots of the DOPS vesicles (1 mL) were added to tubes (11x). Stock solutions containing MePEGA-2000-DSPE N-(2'-O-(ω -monomethoxypolyethylene glycol 2000) hydroxyacetic acid)-1,2distearoyl-sn-glycero-3-phosphoethanolamine) and ATTA8-DOPE were prepared in ethanol or chloroform. Aliquots of each solution containing the mole equivalent of 1%, 2%, 3%, 4% or 5% of half of the total lipid (assuming that the external leaflet = ~50% of the total lipid) were added to the 1 mL DOPS vesicle samples. No polymer-lipid was added to the eleventh DOPS sample. The aliquots were incubated at 37°C for one hour with occasional stirring, and then allowed to cool to room temperature. A UV/visible spectrophotometer was zeroed at 550 nm using the 0% sample. An aliquot of cationic liposomes (0.5 mL) was added to anionic liposomes (0.5 mL) in a cuvette and mixed vigorously. Photometric monitoring was started approximately 3 seconds after mixing. Absorbance measurements were taken at the specified timepoints for the duration of the experiment.

EXAMPLE IV

Synthesis of DPG-S-ATT8-Phe₅

A solution of 1,2-dipalmitoyl-*sn*-glycero-3-succinate (DPG-S) (1 g) in chloroform is treated with N-hydroxysuccinimide (NHS) (0.25 g) and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) (0.35 g) for one hour. The solution is 5 filtered. The filtrate is washed with dilute hydrochloric acid, is dried over magnesium sulphate and filtered. *Octa*-(14-amino- 3,6,9,12-tetraoxatetradecanoic acid) (ATT8) (2.5 g) is added, followed by triethylamine (0.5 mL). The solution is stirred at room 10 temperature for one hour, is washed with dilute hydrochloric acid and then is dried over magnesium sulphate. The solvent is removed by a rotovap. The residue is subjected to column chromatography over silica gel to yield DPG-S-ATT8 as a colorless wax. A solution of DPG-S-ATT8 (170 mg) in chloroform (1 mL) is treated with NHS (12 mg) and EDC (19 mg) for one hour at room temperature. The solution is washed with 15 diluted hydrochloric acid and then is dried over magnesium sulphate. Next, the solution is filtered and the solvent removed under vacuum. The residue is dissolved in water and immediately added to a solution of *penta*-phenylalanine (100 mg) in NaHCO₃ buffer (pH=8.0) (2 mL). The reaction mixture is stirred at room temperature for 1 hour. The reaction mixture is extracted with methylene chloride, dried over anhydrous magnesium sulfate, and then is filtered. The solvent is removed under vacuum. The residue is 20 subjected to column chromatography to yield DPG-S-ATT8-Phe₅ as a colorless powder after lyophilization.

EXAMPLE V

This data demonstrates the use of polyethylene glycol-phosphatidyl-ethanolamines (PEG-PE) and (ATT8-DSPE) to increase the encapsulation efficiency of therapeutic cationic peptides. These results indicate that ATT8 is superior to PEG in 25 encapsulation efficiency. High encapsulation of these peptides can be achieved because of the ability of ATT8-DSPE to provide superior negative surface charge and steric stabilization.

Lipid films (total of 100 mg of lipid) were prepared by dissolving 30 appropriate quantities of individual lipids in 200 to 500 μ L of chloroform, mixing the lipids, then removing the chloroform under high vacuum. Specifically, prepared lipid films were sphingomyelin /cholesterol/PEG-PE (50/45/5 molar ratios; prepared from

53.2 mg sphingomyelin, 26 mg cholesterol and 20 mg PEG-PE) and sphingomyelin/cholesterol/ATTA8-DSPE (50/45/5 molar ratios; prepared from 53.2 mg sphingomyelin, 26 mg cholesterol and 20 mg ATTA8-DSPE) and contained 1 μ Ci of 3H-cholesterylhexadecylether as a radiolabelled tracer. Films were hydrated by the addition of 1.0 mL of IntraBiotics Protegrin IB510 (an antibacterial peptide from IntraBiotics, Sunnyvale, CA) at 10 mg/mL in 10 mM sodium acetate and 300 mM sucrose (pH 4.5) then vortexed extensively for 2 minutes and subjected to five freeze/thaw cycles between -196°C and 65°C at 3-5 minutes each time. 5 μ l were removed for phosphate assay to quantify the phospholipid and for liquid scintillation counting (LSC). These values were used to calculate the specific activity of the different liposomal preparations. The multilamellar vesicles were converted to large unilamellar vesicles by repeated passage, typically 10 times, of the formulations through polycarbonate filters of defined pore size (either 0.2 or 0.1 μ m) at 65°C in a Thermobarrel Extruder.

15 Aliquots of 200-400 μ L of the large unilamellar vesicles containing IB510 were passed over a 20 cm x 1 cm BioGel A-15 m (50-100 mesh) column pre-equilibrated in 150 mM NaCl and 20 mM Hepes (pH 7.5). Liposome-containing fractions were identified by LSC of 100 μ L aliquots of each fraction and the 5-6 fractions with the highest lipid concentrations combined. The concentrations of liposomes and peptide were quantified by LSC and HPLC, respectively. Encapsulation efficiency was calculated from the post-column peptide/lipid ratio divided by the precolumn peptide/lipid ratio.

20 25 Results of this experiment (see Table I) indicate formulations of both IB510 in SM/chol/PEG-PE and SM/chol/ATTA8-DSPE had > 85% recovery of the peptide prior to column chromatography. However ATTA8-DSPE was superior to PEG-PE in encapsulation efficiency.

Table 1.

Formulation (molar ratio)	Peptide/lipid after extrusion (% initial)	Encapsulation efficiency (%)	Final recovery of entrapped peptide (%)
SM/chol/PEG-PE (50/45/5)	96.9	37.2	36.0
SM/chol/ATTA8- DSPE (50/45/5)	84.6	67.2	56.9

EXAMPLE VI

10 This data demonstrates the *in vivo* clearance behavior of ATTA8-DSPE liposomes. Liposomes [DSPC/chol (55:45); DSPC/chol/ATTA8-DSPE (50:45:5); DSPC/chol/MePEGA-2000-DSPE (50:45:5)] labeled with [¹⁴C]-cholesteryl hexadecyl ether were prepared in HBS (Hepes buffered saline; 10 mM Hepes, 150mM NaCl, pH7.4) and diluted to 4.5mM. Aliquots (200 μ L) were administered to ICR mice (6 mice per sample) by tail vein injection. The mice were sacrificed after 19 hours, the blood removed by cardiac puncture and collected in microtainer tubes with EDTA. The samples were centrifuged at 1500xg for 10 minutes and the plasma isolated. Two 100 μ L samples from each mouse were counted in a scintillation counter directly in 5mL of scintillation fluid. The percentage recovery was based on a plasma volume of 4.55% of individual mouse body weight (see, Figure 5). The results indicate that

15 DSPC/chol/ATTA8-DSPE was superior to DSPC/chol/PEG-DSPE as there were more liposomes in circulation using the ATTA8-DSPE.

20

EXAMPLE VII

This example illustrates the synthesis of N- (4-azido-tetra- (14'-amino-3', 6', 9', 12'-tetraoxatetradecanoyl))-1,2-distearoyl-*sn*-3- phosphoethanolamine 15.

With reference to Figure 6, compound 15 was synthesized using a similar procedure as described previously for compound 13, and was isolated as a colorless powder after lyophilization. ^1H NMR (CDCl_3) ^1H NMR (CDCl_3) δ 5.17 (m, 1H), 4.33 (dd, 1H), 4.12 (dd, 1H), 3.8-4.05 (m, 12H), 3.4-3.8 (m, 64H), 3.35 (t, $J = 5\text{Hz}$, 2H), 2.26 (m, 4H), 1.55 (bs, 4H), 1.22 (s, 56H), 0.85 (t, $J=7.5\text{Hz}$, 6H).

10

EXAMPLE VIII

This example illustrates the synthesis of N-(4-azido-octa-(14'-amino-3',6',9',12'-tetraoxatetradecanoyl))-dimyristylamine 16.

With reference to Figure 7, the synthesis of compound 16 requires the synthesis of dimyristylamine 26. A solution of myristic acid (5 g) in benzene (40 mL) was treated with oxalyl chloride (2.5 mL) for 2 hours. The solvent was removed on a rotovap and the residue dissolved in benzene (20 mL). A solution of tetradecylamine 24 (2.5 g) in benzene was added. The solution was warmed to 60°C , stirred and treated with Et_3N (1 mL, slow addition). The reaction mixture was then allowed to stir at room temperature overnight. The suspension was then diluted with water, acidified and extracted with methylene chloride. The organic phase was dried over magnesium sulfate and the solvent removed under vacuum. The residue was passed down a silica gel column in order to remove any unreacted 24, yielding 25 (2 g) as a colorless solid. The product was suspended in ether and treated with excess LiAlH_4 (added slowly until vigorous evolution of gas ceased). The mixture was stirred at room temperature for one hour. Methanol was then slowly added, followed by water and finally enough dilute hydrochloric acid to acidify the mixture. The suspension was extracted with methylene chloride (the precipitate suspends in the organic phase) and the combined organic phases washed with aqueous sodium hydroxide. Column chromatography yielded 26 as a white powder (1.86g). ^1H NMR (CDCl_3) δ 2.55 (t, $J=7.1\text{Hz}$, 6H), 1.45 (m, 4H), 1.23 (s, 44H), 0.85 (t, $J=6.7\text{Hz}$, 6H).

A solution of the acid corresponding to 16 (1.04 g) in methylene chloride (20 mL) was treated with NHS (0.10 g) and DCC (0.12 g) at room temperature for one hour. The solution was filtered and added to a solution of 26 (0.30 g) in methylene chloride (20 mL). Triethylamine (10 drops) was added and the reaction mixture allowed to stir for half an hour. The solution was then washed with dilute hydrochloric acid. The combined organic

fractions were dried under vacuum and the residue redissolved in water, filtered and extracted with methylene chloride. Column chromatography yielded 16 as a colorless oil (0.62g). ¹H NMR (CDCl₃) δ7.2 (bs, ~7H), 4.16 (s, 2H), 3.98 (s, 14H), 3.1-3.7 (m, 132H), 2.2 (bm, 10H), 1.49 (bs, 4H), 1.23 (s, 44H), 0.85 (t, J=6.4Hz, 6H).

5

EXAMPLE IX

This example illustrates the synthesis of N-(4-azido-octa-(14'-amino-3',6',9',12'-tetraoxatetradecanoyl))di(hexadecyl)amine 17.

10 Compound 17 was synthesized from dipalmitylamine using the method described for 16 and was obtained as a colorless oil. ¹H NMR (CDCl₃) δ7.2 (bs), 4.17 (s, 2H), 3.99 (s, 14H), 3.1-3.7 (m, 132H), 1.49 (bm, 4H), 1.22 (s, 52H), 0.85 (t, J=6.52Hz, 6H). Dipalmitylamine was synthesized from hexadecylamine using the method described for 26 and isolated as a white powder. ¹H NMR (CDCl₃) δ2.57 (t, J=7.1Hz, 6H), 1.47 (m, 4H), 15 1.23 (s, 52H), 0.86 (t, J=6.6Hz, 6H).

EXAMPLE X

This example illustrates the synthesis of N-(4-azido-octa-(14'-amino-3',6',9',12'-tetraoxatetradecanoyl))-rac-1',2'-dimyristoyloxypropyl-3-amine 18.

20 With reference to Figure 8, the synthesis of compound 18 proceeds via a glycidol intermediate. Synthesis of rac-3-(N-BOC)-aminopropan-1,2-diol 29 is accomplished by treating rac-Glycidol 27 (15 g) with concentrated ammonia (150 mL) overnight. The solvent was removed on a rotovap and the residue dried by azeotropic removal of water using ethanol. A solution of the residue in ethanol was treated with tert-butoxypyrocarbonate (35 g) and triethylamine (20 mL) for four hours at room temperature. Workup followed by column chromatography yielded 29 as a colorless oil which slowly crystallized on standing. The resultant solid was dried under vacuum, yielding 29 as a colorless crystalline solid (22 g). ¹H NMR (CDCl₃) δ5.39 (m, 1H), 4.08 (m, 1H), 3.94 (m, 1H), 3.70 (m, 1H), 3.52 (m, 2H), 3.17 (m, 2H), 1.40 (s, 9H).

25 30 With reference to Figure 8, the synthesis of N-tert-butoxycarbonyl-1,2- rac-dimyristoyloxypropyl-3-amine 30 proceeded as follows. A suspension of myristic acid (3.0 g) in benzene (50 mL) was treated with oxalyl chloride (1 mL), with occasional warming, until all of the solid was dissolved and gas evolution had largely ceased. The solvent and excess oxalyl chloride was removed on a rotovap. The residue was dissolved in benzene

(50 mL) and treated with **29** (0.86g), followed by triethylamine (1 mL). The mixture was then allowed to stir at room temperature overnight. Workup, followed by column chromatography yielded **30** (1.38g) as a colorless powder. ^1H NMR (CDCl_3) δ 5.07 (m, 1H), 4.73 (m, 1H), 4.25 (dd, J =4.1Hz, J' =11.9Hz, 1H), 4.10 (dd, J =5.7Hz, J' =11.9Hz, 1H), 3.33 (bs, 2H), 2.29 (t, J =7.3Hz, 4H), 1.59 (bm, 4H), 1.42 (s, 9H), 1.24 (s, 44H), 0.86 (t, J =6.5Hz, 6H).

The synthesis of N-tert-butoxycarbonyl-1,2- rac-dipalmitoyloxypropyl-3-amine **31** proceeded as follows. A colorless powder (1.06 g) was synthesized as for **30** from palmitic acid (3.28g). ^1H NMR (CDCl_3) δ 5.07 (m, 1H), 4.73 (m, 1H), 4.25 (dd, J =4.1Hz, J' =11.9Hz, 1H), 4.10 (dd, J =5.7Hz, J' =11.9Hz, 1H), 3.33 (bs, 2H), 2.29 (t, J =7.3Hz, 4H), 1.59 (bm, 4H), 1.42 (s, 9H), 1.24 (s, 48H), 0.86 (t, J =6.5Hz, 6H).

The synthesis of N-tert-butoxycarbonyl-1,2- rac-distearoyloxypropyl-3-amine **32** proceeded as follows. A colorless powder (1.38 g) was synthesized as for **30** from stearic acid (3.00g). ^1H NMR (CDCl_3) δ 5.06 (m, 1H), 4.72 (m, 1H), 4.25 (dd, J =4.1Hz, J' =11.9Hz, 1H), 4.09 (dd, J =5.6Hz, J' =11.9Hz, 1H), 3.32 (bs, 2H), 2.28 (t, J =7.4Hz, 4H), 1.58 (bm, 4H), 1.41 (s, 9H), 1.24 (s, 56H), 0.85 (t, J =6.5Hz, 6H).

General synthesis of N-(rac-2',3'-diacyloxypropyl)ammonium triflouroacetate **33-35** proceeds as follows. Compound **30-32** (~0.90 g) was treated with neat TFA (5mL) for one hour. The solvent was removed on a rotovap and the residue recrystallized from ethanol, yielding **33-35** as fine colorless needles (84 g). **30** (0.90 g), **31** (0.90 g) and **32** (0.81g) yielded **33** (0.84g), **34** (0.85) and **35** (0.74g) respectively.

Synthesis of N-(4-azido-octa-(14'-amino-3',6',9',12'-tetraoxatetradecanoyl))-rac-1',2'- dimyristoyloxypropyl-3-amine **18** proceed as follows. A solution of the acid corresponding to **16** (1.05 g) in methylene chloride was treated with NHS (0.136g) and DCC (0.133 g) at room temperature for 1 hour. The solution was filtered and treated with **33** (0.37 g) and triethylamine (0.5 mL) at room temperature for half an hour. Following workup, **18** was isolated as a colorless oil (0.65 g) after column chromatography. ^1H NMR (CDCl_3) δ 5.10 (m, 1H), 4.20 (dd, J =3.4Hz, J' =12Hz, 1H), 4.06 (dd, partially hidden, J =6.1Hz, J' =12Hz, 1H), 3.95 (s, 16H), 3.2-3.8 (m, 130H), 2.25 (t, J =7.5Hz, 4H), 1.44 (m, 4H), 1.20 (s, 40H), 0.82 (t, J =6.6Hz, 6H).

The synthesis of N-(4-azido-octa-(14'-amino-3',6',9',12'-tetraoxatetradecanoyl))-rac-1',2'- dipalmitoyloxypropyl-3-amine **19** proceeded as follows. Compound **19** was synthesized from **34** (0.39g, 0.121g NHS, 0.133g DCC, 1.01g acid

coresponding to 16) in the same way as 18, yielding 19 as a colorless oil (0.80g). ^1H NMR (CDCl_3) 85.10 (m, 1H), 4.20 (dd, $J=3.4\text{Hz}$, $J'=12\text{Hz}$, 1H), 4.1 (dd, partially hidden, $J=6.1\text{Hz}$, $J'=12\text{Hz}$, 1H), 3.99 (s, 16H), 3.2-3.8 (m, 130H), 2.27 (t, $J=7.4\text{Hz}$, 4H), 1.57 (m, 4H), 1.22 (s, 48H), 0.84 (t, $J=6.2\text{Hz}$, 6H).

EXAMPLE XI

This example illustrates *in vivo* immunogenicity of compounds of the present invention.

15 Female Balb/c mice (6-10 weeks old), 12 per group, were injected intravenously (i.v.) with 200 μ L of 5mM lipids [HBS control; DSPC/cholesterol (55:45); DSPE/cholesterol/MePEGA-2000-DSPE (50:14:5); DSPC/cholesterol/ATTA8-DSPE (50:45:5)]. Four injections were given (at intervals of seven days) over a period of three weeks. A group of mice injected with 200 μ L diluent over course of administration served as a base-line control.

20 Three mice from each group were sacrificed 24 h after each lipid administration. Spleens were harvested and assayed for lipid specific clonal expansion (mitogenicity assay below) and cytokine release (ELISA assay below). The phenotypic profiles of the recovered cells were analyzed by measuring the expression of differentiation (CD22, CD4, CD8, CD11b) and activation (CD25, CD54, CD86, Ly6A/E, MHC-II) markers. Spleen cells (1x10⁶) were

25 stained with appropriate PE-conjugated antibodies (PharMingen, CA) and phenotypic analysis was performed on FACSSort flow cytometer (Becton Dickinson, CA).

The phenotypic profile of spleen cells recovered from mice after the 4th injection following repeated lipid administration is shown in Table 2.

TABLE 2

Formulation	CD4	CD8	CD22	CD11b	CD25
HBS	25.67	12.93	52.45	13.78	1.27
DSPC/chol	22.2	11.92	57.72	13.23	1.11
DSPC/chol/MePEGA-2000-DSPE	21.99	21.99	57.74	13.48	1.36
DSPC/chol/ATTA8-DSPE	21.87	11.09	48.85	13.54	1.36
Formulation	CD54	CD86	MHC-II	Ly6A/E	
HBS	18.51	10.46	57.92	7.75	
DSPC/chol	-	-	-	-	
DSPC/chol/MePEGA-2000-DSPE	-	-	-	-	
DSPC/chol/ATTA8-DSPE	19.48	10.57	54.13	9.4	

EXAMPLE XII

This example illustrates a mitogenicity assay using compounds of the present
5 invention.

The mitogenicity of liposomes was evaluated by measuring cellular immune response following stimulation of primary immune cells *in vitro*. Splenocytes from eight weeks old Balb/c untreated mice were used in cell proliferation assay. Splenocytes were tested for their ability to proliferate upon *in vitro* stimulation with liposomes or with 10 polyclonal activators for T (Concanavalin A; Con A) and B cells (Lipopolysaccharide, LPS). Single-cell suspensions of lymphocytes were prepared from whole spleens in complete RPMI medium, supplemented with 5% heat-inactivated fetal bovine serum (FBS). Viability of cells was examined by trypan blue dye exclusion and exceeded 95% viability. Cells were counted on Colter Counter and were adjusted to a density of 5×10^6 /mL. 100 μ L volumes of the cell 15 suspensions were placed into triplicate flat-bottom wells of 96-well plates along with equal volumes of the appropriate liposomes. Cells were labeled with 1 μ Ci/well of [3 H]-thymidine for 48 h after incubation for 3 days with the test solutions (37°C, 5% CO₂). Cells were harvested on glass filters (Skatron harvester) and levels of incorporated radioactivity were measured in a beta scintillation counter (Beckman, LS 6500). Appropriate controls (mitogens 20 or medium alone) were set up on each plate.

For the cytokine ELISA assays, splenocytes (1×10^6 cells/mL) were cultured in either the presence or absence of various concentrations of lipids in 24-well plates. The supernatants were collected at different times after culture initiation (24 h and 48 h) and the levels of cytokine release were (Interleukin-2 and Interleukin-4) determined by ELISA assays 25 using the protocol and specific anti- interleukin antibodies provided by reagent mini-kit from Endogen (Endogen, MA.). Briefly, 96-well Immulon II plates were coated overnight with anti-IL-2, or anti-IL-4 antibody. Plates were washed with PBS-Tween 20 (0.05%) and

blocked with PBS-Tween 20/BSA(2%) for 1 hour at room temperature. Supernatant samples and standards (diluted in blocking buffer), were added and allowed to incubate overnight. Plates were washed and biotinylated anti-IL-2, or anti-IL-4 antibody, was added. After a 2 h incubation, plates were washed and HRP-Extravidin, followed by TMB, was added to each well. Plates were read at OD₄₅₀. The amount of cytokine was determined by comparing OD of test supernatants to a standard curve constructed from OD of serially diluted cytokine standards.

With regard to Table 3, cell proliferation and cytokine release following *in vitro* re-stimulation of spleen cells with 0.62mM lipid formulations is shown. Cells were recovered from mice after the 4th injection following repeated weekly administrations of buffer or the listed liposome compositions. Re-stimulation was performed with the same compositions used for the treatment. Cells recovered from animals treated with buffer only were treated with all compositions as a control for non specific effects.

TABLE 3

<i>in vivo</i> treatment	<i>in vitro</i> stimulation	³ H	cytokine release	
			DPM	IL-2
HBS	HBS	2544	0.816	0.588
HBS	DSPC/chol	6744	0.382	0.474
HBS	DSPC/chol/MePEGA-2000-DSPE	6085	0.333	0.328
HBS	DSPC/chol/ATTA8-DSPE	6916	0.67	0.321
DSPC/chol	DSPC/chol	2700	0.35	0.521
DSPC/chol/MePEGA-2000-DSPE	DSPC/chol/MePEGA-2000-DSPE	4144	0.44	0.44
DSPC/chol/ATTA8-DSPE	DSPC/chol/ATTA8-DSPE	4618	0.375	0.334

15

EXAMPLE XIII

This example illustrates inhibition of hemolysis of erythrocytes by cationic lipids.

Preparation of sensitized sheep red blood cells (EA cells), an aliquot of whole sheep blood (a 50% solution in Alsever's; Cedarlane) was withdrawn from the stock solution and centrifuged for 10 minutes at 1500rpm. The cells were then washed 3 times with 10 volumes of EDTA-GVB2-. The washed cells were resuspended in a volume of EDTA-GVB2- that is approximately 5 times the volume of the initial aliquot. An aliquot of the suspended cells (100 μ l) of the resuspended cells was mixed with 2.9 mL of distilled water in a cuvette and the absorbance at 541nm measured. The concentration of the cells was adjusted to 1×10^9 cells/mL ($A_{541nm} = 0.385$) with EDTA-GVB2-. The cell suspension was warmed to

37°C in a shaking bath and rabbit anti-sheep red blood cell antibody (hemolysin) was added to give a final antibody dilution of 500 fold. This mixture was incubated for 30 minutes at 37°C. Following the incubation, the cells were centrifuged at 1500 rpm for 5 minutes at 4°C, the supernatant removed and the cells washed with EDTA-GVB2-. The cells were then 5 washed two times with DGVB2+ in order to further remove any free antibody and to introduce cations into the cell suspension. Finally, the cell concentration was adjusted to 2x10⁸ cells/mL ($A_{414nm} = 0.654$) with DGVB2+. Cells were maintained at 4°C at all times after preparation, and were used on the same day.

With regard to Figure 9, inhibition of hemolysis of erythrocytes by cationic 10 lipids is shown. Serial dilutions of DODAC/POPC (50:50, circles), DODAC/POPC/ATTA8-DSPE (50:40:10; diamonds), DODAC/POPC/MePEGA-2000-DSPE (50:40:10; triangles) and DODAC/POPC/MePEGS-2000-Mcer (50:40:10; squares) liposomes (all 20mM in VBS, 100 μ L) were incubated with an equal volume of sheep red blood cells (5×10^5 cells) for 30 min at 37°C. The sample was diluted with 1.0 mL of EDTA-GVB, centrifuged at 1500 rpm 15 for 5 min, and the absorbance of the supernatant analyzed at 410 nm.

EXAMPLE XIV

This example illustrates a complement activation assay.

Activation of the complement system by cationic lipid vesicles was assessed 20 using a two step complement consumption assay previously described by Devine, D.V., Wong, K., Serrano, K., Chonn, A., and Cullis, P.R. (1994) *Liposome complement interactions in rat serum: implications for liposome survival studies*. *Biochim. Biophys. Acta* 1191, 43-51. Briefly, liposomes containing various SBL (steric barrier lipid) were prepared in VBS (20 mM, pH 7.50) and extruded through 2 stacked 100 nm polycarbonate filters using an 25 extrusion apparatus (Lipex Biomembranes, Vancouver, Canada). Serial dilutions of the lipid vesicles (100 μ L aliquoted volume) were added to an equal volume of 5X-diluted normal human serum and incubated for 30 min at 37°C. Samples were subsequently diluted with 300 μ L of ice-cold DGVB2+. Aliquots (100 μ L) were incubated with an equal volume of hemolysin-sensitized sheep red blood cells (5×10^5 cells) for 30 min at 37°C. At the end of 30 the incubation, EDTA-GVB (1 mL) was added to the sample to inhibit further complement activity. Samples were centrifuged at 1500 rpm for 5 min at 4°C to remove non-lysed cells. The supernatant was then analyzed for hemoglobin content at 410 nm using a 96-well plate reader.

With respect to Figure 10, inhibition of complement activation by DODAC/POPC/SBL vesicles is shown, *i.e.*, DODAC/POPC (50:50, circles), DODAC/POPC/ATTA8-DSPE (50:40:10; squares), DODAC/POPC/MePEGA-2000-DSPE (50:40:10; triangles) and DODAC/POPC/MePEGS-2000-Mcer (50:40:10; diamonds).

5

EXAMPLE XV

This example illustrates *in vivo* tolerability of polymer modified cationic liposomes.

Female, ICR mice, 6-8 weeks old were used for tolerability studies. Each time group consisted of at least 4 mice. All animal studies were performed in accordance with the guidelines established by the Canadian Council of Animal Care. The plasma circulation levels of DSPC:CHOL:AL-1:ATTA8-DSPE (20:45:25:10) and DSPC:CHOL:AL-1:PEG-CerC14 (20:45:25:10) containing a radiolabeled lipid marker, [³H]-cholesterylhexadecyl ether, were evaluated at 24 h post administration. Mice received a single bolus dose of liposomes up to 750 mg/kg via intravenous administration in the lateral tail vein. At 24 h, mice were anesthetized with halothane and blood was collected into EDTA tubes after cardiac puncture. Mice were then terminated by cervical dislocation. Plasma levels were determined by standard liquid scintillation techniques. Plasma volumes were estimated to by 5% of total body weight. Tolerability of increasing doses of DSPC:CHOL:AL-1:ATTA8-DSPE (20:45:25:10) and DSPC:CHOL:AL-1:PEG-CerC14 (20:45:25:10) was evaluated by monitoring changes in tissue weights and enzymes typically associated with liver damage. At 24 h post-injection, tissues were excised, trimmed of fat and weighed on an analytical balance. An aliquot of the collected blood was placed in a serum tube, allowed to clot for 30 min at room temperature and assayed kinetically for alanine aminotransferase (ALT), aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) according to the manufacturer's directions (Sigma Diagnostics). Clearance of sterically stabilized liposomes is shown in Figures 11, 12, 13 and 14.

EXAMPLE XVI

30 This example illustrates a picogreen assay.

Picogreen working solution was prepared by diluting 1 μ L of stock solution per mL of HBS. A DNA standard solution was prepared at 20 μ g/mL in water. DNA standards (0-50 μ L) and lipid/DNA samples (3 μ L) were added to tubes. Picogreen working

solution (3 mL) was added to each tube and the fluorescence recorded (T_0) at 520 nm using excitation at 480nm. 10% Triton X-100 (30 μ L) was then added and the fluorescence recorded again (T_f). Entrapped DNA was calculated using the standard curve or with the equation %DNA trapped = 1-100(T_0/T_f)

5 With regard to Figure 15, the effect of SBL on plasmid formulation is shown pINEXL018 was encapsulated in DODAC:DOPE:SBL (n:90-n:10; n = 5 - 8%; SBL = ATTA8-DMAP [black bars] or ATTA8- DSAP [hatched bars]) vesicles by detergent dialysis. Vesicle sizes were measured using a Nicomp Model 370 particle sizer. Encapsulation efficiency was determined using the picogreen assay.

10

EXAMPLE XVII

This example illustrates an antisense formulation of a compound of the current invention.

15 A stock solution of lipid (DSPC/chol/AL-1/SBL, 25:45:20:10 mole ratio, 13 μ mol total lipid) in ethanol (0.4mL) was slowly added to a solution of 20 mer antisense DNA (20 mg/0.6 mL) at 65°C with constant vortexing. The mixture was extruded through two 100nm filters at 65°C as described above. The liposomes were dialyzed (3500M.Wt. cutoff SpectraPor membrane) against citrate buffer (300mM citrate, pH 4.0, 4000 mL) for 1-2 hours, against HBS (pH 7.4, 4000 mL) overnight and then passed down a Sepharose CL-6B 20 DEAE column (3mL in HBS). The lipid content was analyzed by HPLC. Antisense DNA content was determined in 1% Triton X-100 at 260nm using the equation [DNA] (μ g/mL) = $A_{260}/29.57$. Vesicle sizes were determined using a Nicomp Model 370 particle sizer. Figures 16 and 17 illustrate experiments using antisense formulations of the present invention.

25

EXAMPLE XVIII

This example illustrates drug loading using compounds of the current invention.

With regard to Figure 18, liposomes (POPC/chol/SBL (55-n:45:n; n = 0 to 5; SBL = MePEGA-2000-DSPE [solid bars] or ATTA8-DSPE [hatched bars] 25mM) were 30 prepared in citrate buffer (300mM citric acid, pH 4.0). Aliquots (100 μ L) were added to sodium citrate buffer (300mM sodium citrate, pH8.0; 356 μ L). An aliquot (43.5 μ L) from a stock solution of doxorubicin hydrochloride (10.0mg/mL) was immediately added. Aliquots

(10 μ L) of potassium hydroxide solution (1N) were added in short order until the red color turned purple. The solutions were then warmed in a water bath at 60°C for a few minutes with occasional shaking until the solutions turned dark red. The liposome suspensions were immediately passed down Sephadex G-50 columns (HBS, pH 7.4) to exchange buffer and 5 remove any external doxorubicin. Doxorubicin content was assayed at 480nm against a standard curve after lysis in 1% (net) Triton X-100. Lipid content was determined using the phosphate assay. With regard to Figure 18, data represents the mean of two separate experiments. Error bars represent the range.

10

EXAMPLE XIX

This example illustrates cytotoxicity of compounds of the current invention.

In this example, *in vitro* cytotoxicity of ATTA8 was examined. With regard to Figure 19, the cell lines used (Panel A (human cell lines): MB 231, HeLa, Colo 205, U87, B16, 9L; Panel B (rodent cell lines): MCF-7, SKOV-3, and BHK-21; obtained from ATCC) 15 were grown as monolayer cultures in T-75 flasks. The cells were subcultured twice a week at 37°C in an atmosphere containing 5% CO₂ and maintained at a low passage number (5 to 10). The cells used in the assay were plated at 1x10⁴ cells per well (inoculation volume: 100 μ L /well) and left for 24 h at 37°C to resume exponential growth. An equal volume (100 μ L) of either complete culture medium (control wells), or test solution containing twice the final 20 ATTA8 concentration diluted to volume with complete culture medium, was added 24 h later. Final ATTA8 concentrations ranged from between 5 μ M and 1000 μ M. Eight replicate wells for each test concentration were used. Cytotoxicity was evaluated 24 h later by means of the Crystal Violet assay (see, Hogan, M.M. (1997) Measurement of tumor necrosis factor. In *Current protocols in Immunology*, Vol. 1, 6.10.2., Coico, R. (Ed.), John Wiley & Sons, 25 Inc.) In all experiments dose-response curves were plotted (values expressed as percentage of control optical density) and IC₅₀ values (50% inhibitory concentration) were estimated by regression analysis. The experiments were performed in duplicate.

30

EXAMPLE XX

This example illustrates an aggregation-disaggregation assay which is for the study of ionic membrane interactions.

In this example, cationic and anionic liposomes are allowed to mix, resulting in an immediate aggregation event due to charge interactions. The ionic lipids in these


liposomes then slowly (or rapidly) exchange. Disaggregation occurs, under suitable conditions, once enough of the ionic lipid has exchanged to overcome long range ionic interactions between the charged lipids associated with the inner leaflets. In these experiments the polymer-lipids were incorporated into the anionic liposomes either by 5 preformulation or by exchange. The systems investigated included 0-10% SBL (MePEGA-2000-DSPE [Figure 20A, D], ATTA8-DSPE [Figure 20B, E] and ATTA4-DSPE [Figure 20C, F]) in POPC/DOPS/SBL (80-n:20:n) vesicles. The experiment (preformulated) was performed with both POPC/stearylamine (95:5; Figure 20A-C) and POPC/DODAC (95:5; Figure 20D-F) cationic vesicles. Similar behavior was observed when systems containing 10 exchanged in SBL were used. The effects of environmental factors, such as temperature, were shown to be negligible by repeating the 0% experiment as the first and last experiments in the stearylamine data set (Figure 20C). Data for the DODAC systems 0% plot (Figures 20D-F) were obtained on separate days.

All publications, patents and patent applications mentioned in this 15 specification are herein incorporated by reference into the specification in their entirety for all purposes. Although the invention has been described with reference to preferred embodiments and examples thereof, the scope of the present invention is not limited only to those described embodiments. As will be apparent to persons skilled in the art, modifications and adaptations to the above-described invention can be made without departing from the 20 spirit and scope of the invention, which is defined and circumscribed by the appended claims.

WHAT IS CLAIMED IS:

1

1. A compound of Formula I



2

(I)

3 wherein:

4 R is a member selected from the group consisting of hydrogen, alkyl and
5 acyl;6 R¹ is a member selected from the group consisting of hydrogen and alkyl;
7 or optionally,8 R and R¹ and the nitrogen to which they are bound form an azido moiety;9 R² is a member of the group selected from hydrogen, optionally substituted
10 alkyl, optionally substituted aryl and a side chain of an amino acid;11 R³ is a member selected from the group consisting of hydrogen, halogen,
12 hydroxy, alkoxy, mercapto, hydrazino, amino and NR⁴R⁵, wherein R⁴ and R⁵ are
13 independently hydrogen or alkyl;

14 n is 4 to 80;

15 m is 2 to 6;

16 p is 1 to 4; and

17 q is 0 or 1.

1 2. A compound according to claim 1, wherein:


2 R is hydrogen;

3 R¹ is hydrogen;4 R³ is a member selected from the group consisting of halogen, hydroxy,
5 alkoxy, amino, mercapto and hydrazino; m is 4; p is 1; q is 0; and n is 8.

1 3. A compound according to claim 1, wherein:

2 R, R¹ and the nitrogen to which they are bound form an azido moiety; R³
 3 is a member selected from the group consisting of halogen, hydroxy, alkoxy, amino,
 4 mercapto and hydrazino; m is 4; p is 1; q is 0; and n is 8.

1 4. A compound of Formula II:



2 (II)

3 wherein:

4 R¹ is member selected from the group consisting of hydrogen and alkyl;
 5 A is a member selected from the group consisting of hydrogen, alkyl, acyl
 6 and a ligand;
 7 or, optionally, R¹, A, and the nitrogen to which they are bound form an azido moiety;

8 R² is a member of the group selected from hydrogen, optionally substituted
 9 alkyl, optionally substituted aryl and a side chain of an amino acid;

10 B is a member selected from the group consisting of hydrogen, halogen,
 11 hydroxy, alkoxy, amino, NR⁴R⁵, wherein R⁴ and R⁵ are independently hydrogen or alkyl,
 12 mercapto, hydrazino, diacylglycerolyl, dialkylglycerolyl, N,N-dialkylamino, 1,2-
 13 diacyloxy-3-aminopropane, 1,2-dialkyloxy-3-aminopropane and a ligand;

14 n is 4 to 80;

15 m is 2 to 6;

16 p is 1 to 4; and

17 q is 0 or 1.

1 5. A compound according to claim 4, wherein:

2 A and B are independently selected from the group consisting of hydrogen
 3 and a ligand selected from the group consisting of a lipid, a carrier compound, a
 4 bioaffinity compound, an analytically detectable compound, a therapeutically active
 5 compound, an enzyme, a protein, an immune stimulator, a radiolabel, a fluorogen, a

6 biotin, a drug, a hapten, DNA, RNA, a polysaccharide, a liposome, an immunoglobulin
7 and a functional group.

1 6. A compound according to claim 4, wherein n is 8 and m is 4.

1 7. A compound according to claim 6, wherein B is a lipid.

1 8. A compound according to claim 7, wherein said lipid is a
2 phospholipid having a polar head group.

1 9. A compound according to claim 8, wherein B is a
2 phosphatidylethanolamine coupled through a lipid amine group.

1 10. A compound according to claim 4, wherein B is a phospholipid
2 having two acyl carbon chains with at least one unsaturated bond.

1 11. A compound according to claim 4, wherein B is a phospholipid
2 having two acyl carbon chains, said acyl carbon chains being saturated.

1 12. A compound according to claim 4, wherein B is a
2 phosphatidylethanolamine coupled through a lipid amine group, n is 8 and m is 4.

1 13. A compound according to claim 4, wherein:
2 n is 8, wherein for n¹: R¹, A and the nitrogen to which they are bound
3 form an azido group; m is 4; p is 1; and q is 0; and wherein for n²-n⁸: R¹ is hydrogen,
4 m is 4, p is 1; and q is 0; and
5 B is NR⁴R⁵, wherein R⁴ is C₁₄H₂₉ and R⁵ is C₁₄H₂₉.

1 14. A compound according to claim 4, wherein:
2 n is 8, wherein for n¹: R¹, A and the nitrogen to which they are bound
3 form an azido group; m is 4; p is 1; and q is 0; and wherein for n²-n⁸: R¹ is hydrogen,
4 m is 4, p is 1; and q is 0; and
5 B is NR⁴R⁵, wherein R⁴ is C₁₆H₃₃ and R⁵ is C₁₆H₃₃.

1 **15.** A compound according to claim 4, wherein:

2 n is 4, wherein for n¹: R¹, A and the nitrogen to which they are bound
3 form an azido group; m is 4; p is 1; and q is 0; and wherein for n²-n⁴: R¹ is hydrogen,
4 m is 4, p is 1; and q is 0; and

5 B is 1,2-distearoyl-*sn*-glycero-3-phosphoethanolamine.

1 **16.** A compound according to claim 4, wherein:

2 n is 8, wherein for n¹: R¹, A and the nitrogen to which they are bound
3 form an azido group; m is 4; p is 1; and q is 0; and wherein for n²-n⁸: R¹ is hydrogen,
4 m is 4, p is 1; and q is 0; and

5 B is 1,2-dioleoyl-*sn*-glycero-3-phosphoethanolamine.

1 **17.** A compound according to claim 4, wherein:

2 n is 8, wherein for n¹: R¹, A and the nitrogen to which they are bound
3 form an azido group; m is 4; p is 1; and q is 0; and wherein for n²-n⁸: R¹ is hydrogen,
4 m is 4, p is 1; and q is 0; and

5 B is 1,2-distearoyl-*sn*-glycero-3-phosphoethanolamine.

1 **18.** A compound according to claim 4, wherein:

2 n is 8, wherein for n¹: R¹, A and the nitrogen to which they are bound
3 form an azido group; m is 4; p is 1; and q is 0; and wherein for n²-n⁸: R¹ is hydrogen,
4 m is 4, p is 1; and q is 0; and

5 B is 1,2-diacyloxy-3-aminopropane, wherein the acyl groups are C₁₃H₂₇.

1 **19.** A compound according to claim 4, wherein:

2 n is 8, wherein for n¹: R¹, A and the nitrogen to which they are bound
3 form an azido group; m is 4; p is 1; and q is 0; and wherein for n²-n⁸: R¹ is hydrogen,
4 m is 4, p is 1; and q is 0; and


5 B is 1,2-diacyloxy-3-aminopropane, wherein the acyl groups are C₁₅H₃₁.

1 **20.** A compound according to claim 4, wherein:

2 n is 8, wherein for n¹: R¹, A and the nitrogen to which they are bound
 3 form an azido group; m is 4; p is 1; and q is 0; and wherein for n²-n⁸: R¹ is hydrogen,
 4 m is 4, p is 1; and q is 0; and

5 B is 1,2-diacyloxy-3-aminopropane, wherein the acyl groups are C₁₇H₃₅.

1 21. A composition comprising a compound of Formula II:



(II)

2 wherein:

4 R¹ is member selected from the group consisting of hydrogen and alkyl;
 5 A is a member selected from the group consisting of hydrogen, alkyl, acyl
 6 and a ligand;
 7 or, optionally, R¹, A, and the nitrogen to which they are bound form an
 8 azido moiety;

9 B is a member selected from the group consisting of hydrogen, halogen,
 10 hydroxy, alkoxy, amino, NR⁴R⁵, wherein R⁴ and R⁵ are independently hydrogen or alkyl,
 11 mercapto, hydrazino, diacylglycerolyl, dialkylglycerolyl, N,N-dialkylamino, 1,2-
 12 diacyloxy-3-aminopropane, 1,2-dialkyloxy-3-aminopropane, and a ligand;

13 n is 4 to 80;

14 m is 2 to 6;

15 p is 1 to 4;

16 q is 0 or 1; and

17 a lipid-based drug delivery system.

1 22. A composition according to claim 21, wherein:

2 A and B are independently selected from the group consisting of hydrogen,
 3 and a ligand selected from the group consisting of a lipid, a carrier compound, a
 4 bioaffinity compound, an analytical detectable compound, a therapeutically active
 5 compound, an enzyme, a protein, an immune stimulator, a radiolabel, fluorogen, biotin,

6 a drug, a hapten, DNA, RNA, a polysaccharide, a liposome, an immunoglobulin and a
7 functional group.

1 **23.** A composition according to claim 22, wherein:

2 A and B are independently selected from the group consisting of a lipid, a
3 bioaffinity compound, a therapeutically active compound, an enzyme, a protein and a
4 functional group.

1 **24.** A composition according to claim 21, wherein said lipid-based
2 drug delivery system is selected from the group consisting of a liposome, a micelle, a
3 virosome, a lipid-nucleic acid particle, a nucleic acid aggregate and mixtures thereof.

1 **25.** A composition according to claim 24, wherein said lipid-based
2 drug delivery system is a liposome.

1 **26.** A composition according to claim 21, wherein said lipid based
2 drug delivery system comprises lipids selected from the group consisting of vesicle
3 forming lipids, vesicle adopting lipids and mixtures thereof.

1 **27.** A composition according to claim 25, wherein said liposome has a
2 selected average size in the range of between about 0.05 and 0.5 microns.

1 **28.** A composition according to claim 22, wherein B is a lipid.

1 **29.** A composition according to claim 28, wherein n is 8 and m is 4.

1 **30.** A composition according to claim 28, wherein n is 2 to 4 and m
2 is 4.

1 **31.** A composition according to claim 28, wherein said lipid is a
2 phospholipid having a polar head group.

1 32. A composition according to claim 31, wherein said phospholipid
2 is phosphatidylethanolamine coupled through a lipid amine group.

1 33. A composition according to claim 28, wherein said lipid is a
2 phospholipid having two acyl carbon chains which have at least one unsaturated bond.

1 34. A composition according to claim 28, wherein said lipid is a
2 phospholipid having two acyl carbon chains, said acyl carbon chains being saturated.

1 35. A composition according to claim 28, wherein B is a
2 phosphatidylethanolamine coupled through a lipid amine group, n is 8 and m is 4.

1 36. A composition according to claim 25, wherein said liposome
2 contains about 10 to 40 mole percent cholesterol, about 40 to 85 mole percent of a
3 neutral phospholipid, and about 5 to 15 mole percent of a phospholipid derivatized with
4 said compound of claim 4.

1 37. A composition according to claim 25, wherein said liposome
2 contains one or more bioactive agents.

1 38. A composition according to claim 37, wherein said bioactive agent
2 is an anti-tumor compound.

1 39. A composition according to claim 37, wherein said bioactive agent
2 is a gene construct or an oligonucleotide for therapeutic use.


1 40. A composition according to claim 28, wherein B is coupled via an
2 esterase- or peptidase-sensitive linkage.

1 41. A composition according to claim 25, wherein said liposome
2 comprises a surface-bound ligand which is effective to bind specifically and with high
3 affinity to ligand-binding molecules carried on the surface of specific cells.

1 42. A composition according to claim 41, wherein said surface-bound
 2 ligand is an antibody effective to bind specifically and with high affinity to an antigen
 3 which is expressed in a cell in a disease state.

1 43. A lipid-based composition comprising a steric barrier of defined
 2 length.

1 44. A composition according to claim 43 wherein said steric barrier is
 2 a compound of Formula II:



(II)

3 wherein:

4 5 R¹ is member selected from the group consisting of hydrogen and alkyl;

5 6 R² is a member of the group selected from hydrogen, optionally substituted
 7 alkyl, optionally substituted aryl and a side chain of an amino acid;

8 9 A is a member selected from the group consisting of hydrogen, alkyl, acyl
 10 and a ligand;

11 10 or, optionally, R¹, A, and the nitrogen to which they are bound form an
 11 azido moiety;

12 12 B is a member selected from the group consisting of hydrogen, halogen,
 13 hydroxy, alkoxy, amino, NR⁴R⁵, wherein R⁴ and R⁵ are independently hydrogen or alkyl,
 14 mercapto, hydrazino, diacylglycerolyl, dialkylglycerolyl, N,N-dialkylamino, 1,2-
 15 diacyloxy-3-aminopropane, 1,2-dialkyloxy-3-aminopropane, and a ligand;

16 16 n is 4 to 80;

17 17 m is 2 to 6;

18 18 p is 1 to 4; and

19 19 q is 0 or 1.

1 **45.** A method of increasing the blood-circulation time of a
2 parenterally administered lipid-based delivery system, said method comprising:
3 incorporating into said lipid-based delivery system about 0.1 to 20 mole percent of an
4 amphipathic, vesicle-forming or vesicle-adopting lipid or mixtures thereof derivatized
5 with a compound of Claim 4.


1 **46.** A method of administering a bioactive agent parenterally, said
2 method comprising: preparing a suspension of a lipid-based delivery system comprising
3 a vesicle-forming lipid or vesicle-adopting lipid or mixtures thereof and between 0.1 to
4 20 mole percent of a compound of Claim 4, wherein B is an amphipathic, vesicle
5 forming or vesicle adopting lipid or mixtures thereof and a pharmaceutically acceptable
6 amount of a bioactive agent and parenterally administrating said lipid-based system.

1 **47.** A method of delivering a bioactive agent to a target tissue
2 containing a surface-bound, tissue-specific ligand-binding molecule, said method
3 comprising: preparing a suspension of a lipid-based delivery system, said system
4 containing between about 0.1 to 20 mole percent of a vesicle-forming lipid or vesicle
5 adopting lipid or mixtures thereof derivatized with a compound of Claim 4, a
6 surface-bound ligand effective to bind specifically and with high affinity to said
7 ligand-binding molecule, and a pharmaceutically-acceptable amount of a bioactive agent
8 administering said system.

1 **48.** A method according to claim 47, wherein said vesicle-forming
2 lipid or vesicle adopting lipid is a phospholipid.

1 **49.** A method according to 47, wherein said target tissue is a solid
2 tumor carrying a tumor specific antigen, and said surface-bound ligand is an antibody
3 specific for said antigen.

1 **50.** A compound of the Formula III



2 (III)

wherein:

4

R^1 and R^2 are independently selected from the group consisting of hydrogen and alkyl; or, optionally, R , R^1 , and the nitrogen to which they are bound form an azido moiety;

9 R³ is a member selected from the group consisting of hydrogen, halogen,
10 hydroxy, alkoxy, mercapto, hydrazino, amino and NR⁴R⁵, wherein R⁴ and R⁵ are
11 independently selected from the group consisting of hydrogen and alkyl;

12 R⁶ and R⁷ are independently selected from the group consisting of
13 hydrogen, optionally substituted alkyl or optionally substituted aryl, wherein the
14 substituents include aryl, amine, carboxyl, thiol and hydroxy groups:

15 v is 2 to 40;

16 m and r are independently 2 to 6;


17 x and s are independently 1 to 4; and

18 z and t are independently 0 or 1.

1 51. A compound according to claim 50, wherein:

2 R is hydrogen; R¹ is hydrogen; and R³ is a member selected from the
3 group consisting of hydrogen, alkyl, and acyl.

1 52. A compound of Formula IV:



2 (IV)

3 wherein:

4 A is selected from the group consisting of hydrogen, alkyl, acyl and a
 5 ligand;

6 R¹ and R² are independently selected from the group consisting of
 7 hydrogen and alkyl;

8 R⁶ and R⁷ are independently selected from the group consisting of
 9 hydrogen, optionally substituted alkyl and optionally substituted aryl, wherein the
 10 substituents include aryl, amine, carboxyl, thiol and hydroxy groups;

11 B is a member selected from the group consisting of hydrogen, halogen,
 12 hydroxy, alkoxy, amino, NR⁴R⁵, wherein R⁴ and R⁵ are independently hydrogen and
 13 alkyl, mercapto, hydrazino, diacylglycerolyl, dialkylglycerolyl, N,N-dialkylamino, 1,2-
 14 diacyloxy-3-aminopropane, 1,2-dialkyloxy-3-aminopropane and a ligand; and

15 v is 2 to 40;

16 m and r are independently 2 to 6;


17 x and s are independently 1 to 4; and

18 z and t are independently 0 or 1.

1 53. A compound according to claim 52, wherein:

2 A and B are independently selected from the group consisting of hydrogen
 3 and a ligand selected from the group consisting of a lipid, a carrier compound, a
 4 bioaffinity compound, an analytically detectable compound, a therapeutically active
 5 compound, an enzyme, a protein, an immune stimulator, a radiolabel, a fluorogen, a
 6 biotin, a drug, a hapten, DNA, RNA, a polysaccharide, a liposome, an immunoglobulin
 7 and a functional group.

1 54. A composition comprising a compound of Formula IV:



2 wherein:

3 A is selected from the group consisting of hydrogen, alkyl, acyl and a
 4 ligand;

6 R¹ and R² are independently selected from the group consisting of
7 hydrogen and alkyl;

8 R⁶ and R⁷ are independently selected from the group consisting of
9 hydrogen, optionally substituted alkyl and optionally substituted aryl, wherein the
10 substituents include aryl, amine, carboxyl, thiol and hydroxy groups;

11 B is a member selected from the group consisting of hydrogen, halogen,
12 hydroxy, alkoxy, amino, NR^4R^5 , wherein R^4 and R^5 are independently hydrogen or alkyl,
13 mercapto, hydrazino, diacylglycerolyl, dialkylglycerolyl, N,N-dialkylamino, 1,2-
14 diacyloxy-3-aminopropane, 1,2-dialkyloxy-3-aminopropane, a lipid and a ligand; and

15 v is 2 to 40;


16 m and r are independently 2 to 6;

17 x and s are independently 1 to 4;

18 z and t are independently 0 or 1; and

19 a lipid-based delivery system.

1 55. A composition according to claim 54, wherein v is 2 to 4 and B is
2 a lipid.



3 (IV)

4 wherein:
5 A is selected from the group consisting of hydrogen, alkyl, acyl and a


7 R¹ and R² are independently selected from the group consisting of

12 B is a member selected from the group consisting of hydrogen, halogen,
13 hydroxy, alkoxy, amino, NR^4R^5 , wherein R^4 and R^5 are independently hydrogen or alkyl,
14 mercapto, hydrazino, diacylglycerolyl, dialkylglycerolyl, N,N-dialkylamino, 1,2-
15 diacyloxy-3-aminopropane, 1,2-dialkyloxy-3-aminopropane and a ligand;
16 v is 2 to 40;
17 m and r are independently 2 to 6;
18 x and s are independently 1 to 4; and
19 z and t are independently 0 or 1.

1 57. A composition according to claim 4, said composition having at
2 least 2 compounds of Formula II, said compounds having different values of m.


1/21

Fig. 1




2/21

Fig. 2




The dimerization reaction is repeated
a further 2 times to yield the octomer

Fig. 3



4/21


Fig. 4



5/21

Fig. 5

Circulation after 19 hours
4.5 mM, 200 μ L per mouse



6/21

Fig. 6a


15 $n = 3$
13 $n = 7$ 

Fig. 6b



16 $R = C_{14}H_{29}$
17 $R = C_{16}H_{33}$ 

Fig. 6c

18 $R = C_{13}H_{27}$
19 $R = C_{15}H_{31}$
20 $R = C_{17}H_{35}$ 

7/21

Fig. 6d




21 R = C₁₇H₃₅

Fig. 6e

22 R = C₁₃H₂₇23 R = C₁₉H₃₉


8/21

Fig. 7




9/21

Fig. 8




10/21

Fig. 9




11/21

Fig. 10




12/21

Fig. 11




13/21

Fig. 12




14/21

Fig. 13




15/21

Fig. 14




16/21

Fig. 15




17/21

Fig. 16




18/21

Fig. 17



19/21

Fig. 18



20/21

Fig. 19





Fig. 20



INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 98/01185

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K319/127 C07C235/08 C07C247/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 607 978 A (MITSUBISHI CHEM IND) 27 July 1994 see page 4, line 23 - line 32; claims 1-7; examples 1-5 -----	1-12, 21, 23-28, 31-42, 44
X	EP 0 442 372 A (HOECHST AG) 21 August 1991 see page 29; claims 1-10; example 1 -----	1-5, 21, 37-39
X	US 5 135 737 A (KEANA JOHN F W) 4 August 1992 * Abstract, pages 24-27, claims 1, 8, 12-16 * ----- -/-	1-5, 21, 37-39

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

7 June 1999

Date of mailing of the international search report

11 JUN 1999

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl;
Fax: (+31-70) 340-3016

Authorized officer

Rufet, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 98/01185

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 22429 A (LIPOSOME TECHNOLOGY INC ; ALLEN THERESA M (CA); MARTIN FRANCIS J (U) 13 October 1994 see page 10, line 3 - page 18, line 27; claims 1-3; figures 2-9 ---	1, 21-28, 32-42
A	WO 90 04384 A (ROYAL FREE HOSP SCHOOL MED) 3 May 1990 see page 3 - page 5; claims 1-11; example 1 ---	1, 21-28, 32-42
A	US 5 593 622 A (HIROSHI YOSHIOKA ET AL.) 14 January 1997 see column 4 - column 10; claims 1-18 ---	1, 21-28, 32-42
A	US 5 356 633 A (WOODLE MARTIN C ET AL) 18 October 1994 see abstract; claims 1-6; figures 1-5 ---	50-57
A	US 5 324 844 A (ZALIPSKY SHMUEL) 28 June 1994 cited in the application see page 3 - page 7 ---	50-57
A	US 4 426 330 A (SEARS BARRY D) 17 January 1984 cited in the application see the whole document -----	50-55

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA 98/01185

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 43 because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. Claims Nos.: 50-57 (partly) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark: Although claims 45-49 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Claims Nos.: 43

Claim 43 was not searched under Art. 17(2) (a) and (b) PCT, because it relates to compositions, which are defined by functional terms. This claim is therefore unclear and lacks technical disclosure and thus does not fulfil the requirements of Art. 6 PCT. This claim has been searched only insofar as it encompasses subject-matter of dependent claim 44, which is defined in technical terms.

Claims Nos.: 50-57 (partly)

The subject-matter of claims 50-57 does not fulfil the requirements of Art. 5 and 6 PCT.

The compounds or compositions thereof according to formula (III) and (IV) of claims 50 and 52 are not supported by the description, since no example having the following structure: $N-(CH_2CH_2O)_m-CH_2CH_2-N-C(=O)-CH-$ is present in the description.

The use of general terms like: "optionally substituted, ligand, lipide, lipid-based delivery system, protein, immune stimulator, radiolabel, drug, DNA, RNA, liposome...." renders the subject-matter of those claims unclear. The scope of that claims is therefore so broad (billions of possibilities) that a meaningful search is not possible. Therefore the search has been limited to compounds or compositions thereof according to formula (III) and (IV) with clear definitions of the substituents.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-42,44

Heterobifunctional crosslinkers based on formulae (I) and (II).

2. Claims: 50-57

Heterobifunctional crosslinkers based on formula (III) and (IV).

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/01185

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0607978 A	27-07-1994	JP 6220070 A		09-08-1994
		CA 2113914 A		23-07-1994
		US 5556948 A		17-09-1996
		US 5686101 A		11-11-1997
EP 0442372 A	21-08-1991	DE 4004296 A		14-08-1991
		AT 122149 T		15-05-1995
		DE 59105344 D		08-06-1995
		DK 442372 T		25-09-1995
		ES 2074179 T		01-09-1995
US 5135737 A	04-08-1992	US 4863717 A		05-09-1989
		US 5412148 A		02-05-1995
		US 5567411 A		22-10-1996
		US 5252317 A		12-10-1993
WO 9422429 A	13-10-1994	US 5527528 A		18-06-1996
		AU 6527294 A		24-10-1994
		US 5620689 A		15-04-1997
WO 9004384 A	03-05-1990	AT 104846 T		15-05-1994
		DE 68915001 D		01-06-1994
		DE 68915001 T		04-08-1994
		EP 0445131 A		11-09-1991
		EP 0572049 A		01-12-1993
		JP 4501117 T		27-02-1992
US 5593622 A	14-01-1997	JP 2049324 C		25-04-1996
		JP 2149512 A		08-06-1990
		JP 7020857 B		08-03-1995
		US 5676971 A		14-10-1997
		US 5846458 A		08-12-1998
		AU 616040 B		17-10-1991
		AU 3948789 A		15-02-1990
		DE 68919772 D		19-01-1995
		DE 68919772 T		13-07-1995
		EP 0354855 A		14-02-1990
		ES 2064470 T		01-02-1997
		AU 640298 B		19-08-1993
		AU 1007792 A		27-02-1992
US 5356633 A	18-10-1994	US 5013556 A		07-05-1991
		US 5213804 A		25-05-1993
		AT 152614 T		15-05-1997
		AU 5323194 A		26-04-1994
		CA 2146565 A,C		14-04-1994
		DE 69310527 D		12-06-1997
		DE 69310527 T		04-12-1997
		EP 0662820 A		19-07-1995
		ES 2104184 T		01-10-1997
		WO 9407466 A		14-04-1994
		AT 115401 T		15-12-1994
		AT 122229 T		15-05-1995
		AU 642679 B		28-10-1993
		AU 6637490 A		16-05-1991
		AU 654120 B		27-10-1994
		AU 6898291 A		16-05-1991
		CA 2067133 A,C		21-04-1991

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/01185

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5356633	A	CA 2067178 A,C DE 69015207 D DE 69015207 T DE 69019366 D DE 69019366 T DK 496835 T EP 0496813 A EP 0496835 A ES 2071976 T FI 921763 A FI 921764 A GR 3017060 T HK 14097 A IL 96069 A IL 96070 A JP 10001431 A JP 2667051 B JP 5501264 T JP 5505173 T KR 134982 B LU 88854 A NO 304644 B US 5527528 A WO 9105545 A WO 9105546 A US 5620689 A US 5225212 A US 5843473 A		21-04-1991 26-01-1995 04-05-1995 14-06-1995 05-10-1995 17-07-1995 05-08-1992 05-08-1992 01-07-1995 21-04-1992 21-04-1992 30-11-1995 14-02-1997 08-12-1995 30-03-1995 06-01-1998 22-10-1997 11-03-1993 05-08-1993 22-04-1998 11-03-1997 25-01-1999 18-06-1996 02-05-1991 02-05-1991 15-04-1997 06-07-1993 01-12-1998
US 5324844	A	28-06-1994	US 5122614 A US 5612460 A AU 5526690 A CA 2053317 A,C EP 0470128 A EP 0893439 A JP 2875884 B JP 4504872 T WO 9013540 A US 5808096 A	16-06-1992 18-03-1997 29-11-1990 20-10-1990 12-02-1992 27-01-1999 31-03-1999 27-08-1992 15-11-1992 15-09-1998
US 4426330	A	17-01-1984	CA 1214180 A EP 0072111 A JP 1474142 C JP 58049393 A JP 63020436 B US 4534899 A	18-11-1986 16-02-1983 18-01-1989 23-03-1983 27-04-1988 13-08-1985